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Introduction 
 
The Centers for Disease Control and Prevention (CDC) receives, analyzes, and disseminates 
data on CDC-funded HIV testing, linkage to HIV medical care, and HIV prevention services. 
Test-level data are reported by CDC grantees through the National HIV Prevention Program 
Monitoring and Evaluation (NHM&E) system. These data are used to describe the 
demographics of persons tested and other programmatic activities that are funded by CDC, 
including linkage to HIV medical care, partner services, and HIV prevention services. The 
report on CDC-Funded HIV Testing: United States, Puerto Rico & U.S. Virgin Islands, 2012 
(hereafter: 2012 annual HIV testing report) summarizes the test event-level NHM&E data for 
CDC-funded testing events in the United States and dependent areas (Puerto Rico and U.S. 
Virgin Islands).  
 
This report includes HIV testing data from 61 CDC-funded health department jurisdictions 
and directly-funded community-based organizations (CBOs). It would not be possible without 
the collaboration, dedication and hard work of grantees from all state, territorial and local 
health departments and CBOs. The Testing Monitoring and Evaluation Team (TMET) in the 
Division of HIV/AIDS Prevention’s (DHAP) Program Evaluation Branch (PEB) reviewed the 
completeness and quality of the HIV testing data submitted by grantees to determine data 
for inclusion in this report. CDC staff worked with all health department grantees to ensure 
that their jurisdiction’s HIV testing data were complete and of high quality. Test-level data 
are reported from 59 of 61 health department jurisdictions, representing the highest number 
of jurisdictions reporting test-level data in an annual HIV testing report to date. Aggregate 
data are reported for Michigan and Oregon health department jurisdictions in this report 
because they were unable to submit complete test-level data for 2012.1  
 
NHM&E HIV testing data are used in conjunction with other information (e.g., progress 
reports, surveillance data, and census data) by HIV program managers and policy makers, 
HIV testing service providers, CDC project officers, evaluators, researchers, and others 
interested in the public health implications of HIV prevention program activities. These data 
can be used to learn from our work, inform programmatic activities, and document the 
progress of programs toward local, state and national HIV prevention goals. DHAP’s NHM&E 
HIV testing data are used at the national and local levels for HIV prevention policy, program 
decision making, program monitoring, evaluation activities, research, presentations, and 
reports.  
 
This report includes data submitted to CDC for HIV testing funded by the following six 
program announcements: PS 12-1201 funded all 61 health department (HD) jurisdictions for 
HIV prevention programs (category A), 36 HD jurisdictions for expanded HIV testing services 
for disproportionately affected populations (category B) and 30 HD jurisdictions for 
demonstration projects to implement and evaluate innovative, high-impact HIV prevention 
interventions and strategies (category C); PS11-1117 funded 12 HD jurisdictions with the 
highest number of people living with AIDS for enhanced HIV prevention planning 
(ECHPP); PS12-1210 funded 8 HD jurisdictions to conduct HIV testing and continuum of care 
services among racial and ethnic minorities (CAPUS); PS 08-0803 directly funded CBOs in 
Puerto Rico and the U.S. Virgin Islands to provide HIV testing services; PS 10-1003 directly 
funded CBOs for HIV prevention interventions; and PS 11-1113 directly funded CBOs to 
implement HIV prevention projects for young gay, bisexual, and other men who have sex 
                                                          
1 Aggregate data were presented for Atlanta in Table 1, but test-level data were presented in the 
remaining tables of the 2012 annual HIV testing report. 
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with men (collectively referred to as MSM) of color and young transgender persons of color 
in CBOs.  
HIV Testing and Care Continuum  
 
The 2012 annual HIV testing report presents data on the HIV testing and care continuum. 
The continuum begins with an HIV testing event and the identification of an HIV-positive 
person, followed by linkage to important HIV prevention and treatment services. The 2012 
annual HIV testing report presents data from the HIV testing domains portrayed in the 
darker shade below. 
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Both percentages are presented to provide 
a better indication of how missing/invalid 
data impact monitoring of programs. 
What’s New in the 2012 Report? 
 
Changes were made from the 2011 report to address the evolving scientific evidence, 
programmatic priorities, and needs of programs to access, interpret, and use their data.  
 
Changes include reporting of the following: 
 
• All newly identified HIV-positive persons, rather than newly identified confirmed HIV-
positive persons  
• Target populations instead of risk categories (i.e., MSM, heterosexual, injection drug 
use (IDU), transgender) 
• Data on persons who were previously diagnosed as HIV-positive, including HIV 
testing events, HIV positivity, those already in care, and linkage to HIV medical care 
• The HIV testing and care continuum by health department jurisdictions 
• Data on linkage to HIV medical care within 90 days, in addition to linkage to HIV 
medical care within any timeframe, which includes linkage within 90 days 
• Data on newly identified HIV-positive persons who were interviewed for partner 
services, in addition to referral to partner services 
•  HIV testing and care indicators table for 2010–2012 using new calculations (Table 
16) 
 
Calculations of the HIV Testing Indicators 
 
In addition to the reporting of new indicators, the 2012 annual HIV testing report also 
reflects changes that were made to the calculation of key indicators, including HIV testing 
events, confirmed HIV-positive persons, newly identified HIV-positive persons, linkage to 
HIV medical care, referral to partner services, and referral to HIV prevention services. 
Definitions for these indicators are presented in the Technical Notes. Changes were made to 
address evolving priorities for program monitoring and interpretation of data. For more 
information regarding these changes, please contact the NHM&E Service Center at 1-855-
374-7310 or NHMEservice@cdc.gov.  
 
Missing/Invalid Data 
 
Missing/invalid data are important to 
consider when monitoring and evaluating 
programs. The minimum percentage is 
calculated by including missing/invalid 
data in the denominator, an approach 
which underestimates performance. The 
maximum percentage is calculated by 
excluding missing invalid/data from the 
denominator, which overestimates 
performance. In addition to providing the 
minimum and maximum percentages for 
these HIV testing indicators, the 
percentages for missing/invalid data are 
presented. 
To address this issue, this report presents 
a range of percentages for the following 
indicators: 
 
• Receipt of HIV test results 
• Linkage to HIV medical care within 90 
days and linkage to HIV medical care 
within any timeframe 
• Referral and interview for partner services 
• Referral to HIV prevention services 
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Report Content and Organization 
 
The content of this report addresses the first three goals of the National HIV/AIDS Strategy 
(NHAS) and the DHAP Strategic Plan, specifically: 
 
• Reduce the number of persons who become HIV infected 
• Increase access to care and improve health outcomes for persons living with HIV 
• Reduce HIV-related health disparities 
 
The report also informs national HIV testing monitoring and evaluation questions for CDC-
funded HIV testing programs in 2012, including stratification by jurisdictions and by 
demographic characteristics. Examples of the monitoring and evaluation questions that the 
2012 annual HIV testing report answers include the following: 
 
• How many CDC-funded testing events were conducted in the United States?  
• How many persons were HIV-positive? 
• How many persons were newly identified HIV-positive? 
• How many newly identified HIV-positive persons were linked to HIV medical care 
within 90 days or within any timeframe? 
• How many newly identified HIV-positive persons were referred and interviewed for 
partner services? 
• How many newly identified HIV-positive persons were referred to HIV prevention 
services? 
 
This report contains 4 figures and 16 tables, which include the following: 
 
• CDC-funded HIV testing events and the continuum of HIV testing and care activities 
among newly identified HIV-positive persons 
• HIV positivity, including total number of HIV-positive persons, persons previously 
diagnosed HIV-positive, and newly identified HIV-positive persons 
• Continuum of HIV testing and care activities among newly identified HIV-positive 
persons, including stratifications by test setting and target populations  
 
Data presented include CDC-funded HIV testing events conducted in 2012 in 61 health 
department jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands that 
were submitted to CDC as of October 7, 2013.2 To provide the most complete estimate of 
CDC-funded testing events in 2012, Table 1 presents both test-level (58 health department 
jurisdictions) and aggregate (3 health department jurisdictions) data. All other tables display 
only test-level data (i.e., data for individual test records) and exclude 2 jurisdictions 
(Michigan and Oregon) for which self-reported aggregate data were used due to an 
incomplete 2012 test-level data submission.3 Results are summarized in text, figures, and 
tables. Please review the technical notes, which are provided to assist with interpretation. 
Readers are encouraged to review all table titles and footnotes carefully to ensure a 
complete understanding of the data presented. 
 
                                                          
2 Data from testing events conducted in 2012 and were submitted by October 2013. 
3 Aggregate data were reported only for Atlanta in Table 1. 
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Highlights of the 2012 Report 
HIV Testing Events  
• Approximately 3.4 million CDC-funded HIV testing events were conducted by the 61 
health department jurisdictions in the United States, Puerto Rico, and the U.S. Virgin 
Islands (Table 1). 
• Of the approximately 3.3 million CDC-funded testing events with test-level data, 
2,297,501 (69.9%) were conducted in healthcare and correctional facilities and 985,611 
(30%) were conducted in non-healthcare facilities (Table 2). 
HIV-Positive Testing Events 
• 26,696 (0.8%) HIV-positive testing events were conducted in the 61 health department 
jurisdictions in the United States, Puerto Rico and the U.S. Virgin Islands (Table 1).  
• 8,048 (0.2%) were testing events conducted among those who had been previously 
diagnosed as HIV-positive (Table 3). 
 
Newly Identified HIV-Positive persons4 
• 16,976 (0.5%) persons were newly identified HIV-positive (Table 4). 
• 13,754 (0.4%) persons were newly identified confirmed HIV-positive (Table 1). 
• The highest proportion of newly identified HIV-positive persons were among MSM who 
inject drugs (3.7%), MSM (3.1%), and transgender persons who inject drugs (3.1%) 
(Table 6).  
HIV Testing and Care Continuum among Newly Identified HIV-Positive Persons5  
• 89%–95% received their HIV test results. 
• 36%–82% were linked to HIV medical care within 90 days (Table 4). 
• 51%–67% were linked to HIV medical care within any timeframe (Table 4). 
• 66%–81% were referred to partner services (Table 5). 
• 34%–61% were interviewed for partner services (Table 5). 
• 52%–74% were referred to HIV prevention services (Table 5). 
Missing or Invalid Data  
• 7% for receipt of HIV test results. 
• 56% for linkage to HIV medical care within 90 days (Table 4). 
• 24% for linkage to HIV medical care within any timeframe (Table 4). 
• 19% for referral to partner services (Table 5). 
• 44% for interviewed for partner services (Table 5). 
• 30% for referral to HIV prevention services (Table 5). 
 
 
 
 
                                                          
4 Testing events cannot be reported at the person-level because one person may have received multiple 
testing events in a reporting year.  However, in this report newly identified HIV-positive testing events are 
referred to as “persons,” as a newly identified HIV positive testing event should not occur more than once 
per person.   
5  Both percentages are presented to provide a better indication of how missing/invalid data impact 
monitoring of programs. 
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Programmatic Impact6  
 
Compared with the 2011 annual HIV testing report: 
 
• Referral to partner and HIV prevention services increased in 2012, although the 
percentage of newly identified HIV-positive persons linked to HIV medical care remained 
below the NHAS and DHAP Strategic Plan objective of 85%. There is need for continued 
improvement on HIV service delivery for HIV-positive persons. 
  
• Overall, missing/invalid data across all of the HIV testing and care continuum indicators 
decreased. Specifically, there was a lower percentage of missing data for receipt of HIV 
test results (7% in 2012 vs. 14% in 2011), linkage to HIV medical care within any 
timeframe (24% in 2012 vs. 46% in 2011), referral to partner services (19% in 2012 vs. 
27% in 2011) and referral to HIV prevention services (30% in 2012 vs. 46% in 2011). 
  
• Despite the decrease in missing/invalid data, continued improvement in data 
completeness is needed, particularly for linkage to medical care (i.e., linkage within 90 
days and linkage within timeframe), interview for partner services, and referral to HIV 
prevention services. High-quality and complete data strengthen the ability to monitor and 
improve CDC-funded HIV testing programs as measured by these important programmatic 
indicators. 
                                                          
6 In the 2011 testing report, only the maximum percentage for each indicator was presented.  Therefore, 
comparisons are only made for the maximum percentages.  Linkage to HIV medical care within 90 days 
and interview for partner services are new indicators for the 2012 report. 
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Results 
 
In 2012, 3,379,152 CDC-funded HIV testing events were conducted among the 61 health 
department jurisdictions in the United States, Puerto Rico and U.S. Virgin Islands (Table 1). Of 
those HIV testing events, complete test-level NHM&E data were submitted to CDC for 
3,287,024 testing events from 59 jurisdictions (Table 4). Aggregate-level HIV testing data are 
reported for Michigan and Oregon.   
 
More testing was conducted in health care and correctional facilities (2,297,501; 69.9%) than 
in non-health care settings (985,611; 30%) (Table 2). More than half of all tests were 
conducted in the South (1,935,693; 58.9%). More females (1,679,449; 51.1%) were tested 
than males (1,574,184; 47.9%), but males were much more likely to be newly identified HIV-
positive (0.8%) than females (0.2%).  
 
By age group, the largest proportion of HIV testing was among persons aged 20–29 years 
(1,346,543; 41%), and the lowest was among persons younger than 13 years (5,133; 0.2%). 
By race/ethnicity, the largest proportion of testing was among blacks/African Americans 
(1,444,796; 44%), followed by whites (895,814; 27.3%) and Hispanics/Latinos (686,757; 
20.9%). Lastly, a rapid test was used for 56.5% of HIV testing events (Table 6).  
 
HIV-Positive Testing Events  
 
In 2012, 26,696 HIV-positive testing events were conducted, for a positivity percentage of 
0.8%. Preliminary HIV-positive test results accounted for 3,826 (0.1%) of the total testing 
events, and confirmed HIV-positive test results accounted for 24,136 (0.7%) of the total 
testing events (Table 1).  
 
Previous HIV-Positive Testing Events 
 
Previous HIV-positive testing events accounted for 0.2% (8,048) of the total testing events, 
and of those who had previously tested HIV-positive, 6.8% (546) reported that they were 
already in HIV medical care. Houston (1.1%), Atlanta (0.9%), San Francisco (0.8%), 
Washington (0.7%), and Mississippi (0.6%) were the health department jurisdictions most 
likely to test previously diagnosed HIV-positive persons. Among previously diagnosed HIV-
positive persons, 37.8%–85.6% were linked to HIV medical within 90 days after diagnosis, 
and 55.4%–78.1% were linked to HIV medical care within any timeframe (Table 3). 
 
Newly Identified HIV-Positive Persons 
 
Among 2012 HIV testing events, 16,976 (0.5%) were newly identified HIV-positive (Table 4), 
of which 13,754 (81%) were confirmed HIV-positive (Table 1). The remaining sections of the 
report present data only for newly identified HIV-positive persons, including both preliminary 
and confirmed HIV-positive persons.  
 
The target populations with the highest newly identified HIV positivity percentages were MSM 
who inject drugs (3.7%), MSM (3.1%), transgender persons who inject drugs (3.1%), and 
transgender persons (1.7%).  
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Other groups with newly identified HIV positivity percentages greater than the national 
average of 0.5% were males (0.8%), persons aged 40–49 (0.7%) and 30–39 (0.6%) years, 
multi-racial persons (0.7%) and black/African American persons (0.6%). 
 
By geographic region, the highest percentages of HIV positivity were in the U.S. dependent 
areas (1.3%) and the West (0.7%). By test setting, non-health care facilities (0.7%) had HIV 
positivity percentages greater than the national average, whereas health care facilities had a 
lower percentage (0.4%) (Table 6). By health department jurisdiction, newly identified HIV 
positivity was highest in Atlanta (1.7%), Illinois (excludes Chicago) (1.6%), Puerto Rico 
(1.5%), and Arkansas (1.2%) (Table 4). HIV positivity percentages for newly identified 
persons are displayed in Figure 1 by demographic characteristics.  
 
HIV Testing and Care Continuum for Newly Identified HIV-Positive Persons 
 
Receipt of HIV Test Results 
 
Among all newly identified HIV-positive persons, 88.9%–95.4% received their HIV test 
results. By test setting type, 84.5%–94.6% received their results in health care and 
correctional facilities, compared with 95.2%–96.5% in non-health care facilities.  
  
Linkage to HIV Medical Care 
 
Because of the prevention and treatment benefits of early initiation of antiretroviral therapy, 
the objectives and programmatic priorities of NHAS and the DHAP Strategic Plan are to link all 
HIV-positive persons into HIV medical care within 90 days after diagnosis. A goal of NHAS is to 
have 85% of all newly diagnosed persons linked to medical care within 90 days of diagnosis by 
2015. Based on a joint letter from Health Resources and Services Administration (HRSA) and 
CDC, all newly identified HIV-positive persons, including those with a preliminary HIV positive 
test result, should be linked to HIV medical care. Given continuing program and data quality 
challenges related to health departments ascertaining and documenting linkage to HIV medical 
care within 90 days, linkage data in this report are presented for both linkage to HIV medical 
care within 90 days and linkage within any timeframe (including  linkage within 90 days). 
 
Among newly identified HIV-positive persons, 36%–82.2% were linked to HIV medical care 
within 90 days (Table 4). Percentages for linkage to HIV medical care within 90 days varied 
when demographic characteristics and missing/invalid data were taken into account. 
 
• Age: 34.8%–80.8% of persons aged 20-29 years and 36.1%–84.1% of persons aged 30-
39 years were linked to HIV medical care within 90 days, and persons younger than 13 
years were least likely to be linked (22.2%-80%) (Table 6). 
 
• Gender: Males (36.5%–82.6%) were linked within 90 days at rates similar to those of 
females (35%–81.4%) (Table 6). 
 
• Test setting: Rates of linkage within 90 days were similar among persons tested in 
health care and correctional facilities (36.4%–81.7%) and persons tested in non-health 
care facilities (35.6%–83.1%) (Tables 6, 8, 10).  
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• Race/ethnicity: Hispanics/Latinos (45.1%–88.5%) were linked within 90 days more 
than whites (36.7%-85.6%) and blacks/African Americans (33.4%-78.8%) (Table 6). 
 
• U.S. geographic region: Persons in the U.S. dependent areas (81.2%–95.6%) were 
linked within 90 days more than persons in other regions, and those in the South were 
least likely to be linked (29.9%–80%) (Table 6). 
 
 
Among newly identified HIV-positive persons, 51.3%–67.1% were linked to HIV medical care 
within any timeframe (Table 4). Percentages for linkage to HIV medical care within any 
timeframe varied when demographic characteristics and missing/invalid data were taken into 
account. 
 
• Age: Persons in age groups 20–29 (50.8%–67.5%) and 30–39 (53.5%–68.9%) were 
linked within any timeframe more than persons in other age groups. Persons younger 
than 13 years were least likely to be linked (33.3%–54.5%) (Table 6). 
 
• Gender: Males (52.2%–67.5%) were linked within any timeframe more than females 
(48.2%–65.9%) (Table 6). 
 
• Test setting: Rates of linkage within any timeframe were similar among persons tested 
in health care and correctional facilities (51.6%–67.9%) and persons tested in non-
health care facilities (50.8%–66.1%) (Tables 6, 8, 10). 
 
• Race/ethnicity: Hispanics/Latinos (63.5%–76.6%) were linked within any timeframe 
more than whites (52.5%–67.1%) and blacks/African Americans (46.6%–63.8%) 
(Table 6). 
 
• U.S. geographic region: Persons in the U.S. dependent areas (82.1%–86.1%) were 
linked within any timeframe more than persons in other regions, and those in the 
South were least likely to be linked (44.5%–60.6%) (Table 6). 
 
Missing/invalid data create challenges for determining true linkage percentages and addressing 
progress toward achieving the goal of 85% linkage. Continued improvement in data 
completeness and quality is needed for linkage and for all HIV testing indicators to determine 
whether CDC-funded HIV testing programs meet the NHAS goal.  
 
Referral to Partner Services 
 
After receiving an HIV-positive test result, persons are referred to partner services. Some 
programs may have partner services available on-site, but others may refer the person to 
another agency or clinic. Among all newly identified HIV-positive persons, 65.7%–81.1% were 
referred to partner services in 2012 (Table 5). Percentages for referral to partner services 
varied when demographic characteristics and missing/invalid data were taken into account. 
 
• Age: 68.5%–83.9% of persons aged 20–29 years and 65.3%–81.2% of persons aged 
30–39 years were referred to partner services, and persons younger than 13 years were 
least likely to be referred (50%–52.9%) (Table 7). 
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• Gender: Males (66.4%–81.7%) were referred to partner services more than females 
(62%–78.1%) (Table 7). 
• Test setting: Rates of referral to partner services were similar among persons tested in 
health care and correctional facilities (65.8%–81.8%) and persons tested in non-health 
care facilities (65.6%–80.1%) (Tables 7, 9, 11). 
 
• Race/ethnicity: Hispanics/Latinos (68.5%–86%) were referred to partner services 
more than whites (67.4%–82.6%) and blacks/African Americans (64.8%–79.7%) 
(Table 7). 
 
• U.S. geographic region: Persons in the West (76.9%–90.7%) were referred to partner 
services more than persons in the South (62.5%–80.5%) and in the Northeast 
(56.3%–66.7%) (Table 7). 
 
Interview for Partner Services 
 
In addition to referral to partner services, it is necessary to monitor whether persons were 
interviewed for partner services so that essential HIV services (e.g., testing, referral, and 
linkage) can be provided to both the person and his/her partner(s), as needed.  
 
Interview for partner services is a new indicator in the 2012 annual HIV testing report. Among 
all newly identified HIV-positive persons, 34.1%–60.7% were interviewed for partner services 
in 2012 (Table 5). Percentages for interviewed for partner services varied when demographic 
characteristics and missing/invalid data were taken into account. 
 
• Age: 35.2%–64.9% of persons aged 20–29 years and 33.5%–60.5% of persons aged 
30–39 years were interviewed for partner services, and persons younger than 13 years 
were least likely to be interviewed (22.2%–33.3%) (Table 7). 
 
• Gender: Males (34.2%–61.3%) were interviewed for partner services more than females 
(33.4%–57.8%) (Table 7). 
 
• Test setting: Persons tested in health care and correctional facilities (35.4%–63.4%) 
were interviewed for partner services more than persons tested in non-health care 
facilities (32.1%–56.8%) (Tables 7, 9, 11). 
 
• Race/ethnicity: Hispanics/Latinos (39.5%–67.1%) were interviewed for partner 
services more than whites (35%–61.8%) and blacks/African Americans (33.1%–
59.6%) (Table 7). 
 
• U.S. geographic region: Persons in the U.S. dependent areas (84.7%–87.3%) were 
interviewed for partner services more than persons in other regions. Persons in the 
Northeast were least likely to be interviewed (17.5%–34.1%) (Table 7). 
Referral to HIV Prevention Services 
 
After receiving an HIV-positive test result, persons should be referred to HIV prevention 
services. HIV prevention services include services intended to reduce the risk of transmitting or 
acquiring HIV infection (e.g. prevention counseling, evidence-based behavioral interventions, 
risk-reduction counseling). Among all newly identified HIV-positive persons, 52.2%–74.1% 
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were referred to HIV prevention services in 2012 (Table 5). Percentages for referral to HIV 
prevention services varied when demographic characteristics and missing/invalid data were 
taken into account. 
 
• Age: 53.2%–75.6% of persons aged 20–29 years and 52.6%–73.4% of persons aged 
30–39 years were referred to HIV prevention services, and persons younger than 13 
years were least likely to be referred (38.9%–50%) (Table 7). 
 
• Gender: Males (53.5%–74.7%) were referred to HIV prevention services more than 
females (47.5%–72.9%) (Table 7). 
 
• Test setting: Rates of referral to HIV prevention services were similar among persons 
tested in health care and correctional facilities (53.1%–73.6%) and persons tested in 
non-health care facilities (51%–75%) (Tables 7, 9, 11). 
 
• Race/ethnicity: Hispanics/Latinos (57.4%–77.5%) and whites (57.3%–74.3%) were 
referred to HIV prevention services more than blacks/African Americans (49.6%–73.7%) 
(Table 7). 
 
• U.S. geographic region: Persons in the Midwest (69.6%–84.2%) and in the U.S. 
dependent areas (77.3%–78%) were referred to HIV prevention services more than 
persons in the Northeast (53.5%–69.2%) and in the South (45.1%–72.2%) (Table 7). 
Target Populations 
 
Target population categories include: 1) MSM who report injection drug use, 2) MSM, 3) 
transgender persons who report injection drug use, 4) transgender persons, 5) persons who 
report injection drug use, 6) heterosexual males, and 7) heterosexual females. The process 
used to create these categories is described further in 
the ‘Technical Notes’ section.  
 
These categories are mutually exclusive and were 
calculated on the basis of the person’s gender and self-
reported sexual behavior of the person.  
 
Ten percent (329,323) of HIV testing events were 
conducted among MSM, transgender, and persons who 
report injection drug use (Table 6). The data for the HIV 
testing and care continuum are presented below for 
target populations, followed by more detailed information for MSM and heterosexual females. 
 
• Receipt of HIV test results: 93.2%–96.8% of MSM, 74.4%–91.3% of transgender 
persons, and 86.7%–94.2% of heterosexual females received their HIV test results. 
• Linkage to HIV medical care within 90 days: 44.5%–84.9% of MSM, 37.4%–85.5% of 
transgender persons, and 41.1%–81.7% of heterosexual females were linked in 90 
days (Table 6). 
 
• Linkage to HIV medical care within any timeframe: 58.1%–72.6% of MSM, 50.5%–
69.1% of transgender persons, and 53.2%–70.3% of heterosexual females were linked 
within any timeframe (Table 6). 
Data to classify persons into 
one of these categories are 
required to be collected for 
all test events conducted in 
non-health care settings and 
are only required to be 
collected for HIV-positive 
persons in health care 
settings.   
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• Referral to partner services: 77.9%–86.1% of MSM, 65.8%–78.1% of transgender 
persons, 71.5%–82.2% of heterosexual females were referred to partner services 
(Table 7). 
 
• Interview for partner services: 42%–67.5% of MSM, 22.6%–46.7% transgender 
persons, and 39.6%–63.2% of heterosexual females were interviewed for partner 
services (Table 7). 
 
• Referral to HIV prevention services: 63.6%–78.8% of MSM, 58.4%–73.5% of 
transgender persons, and 54.5%–76.4% of heterosexual females were referred to HIV 
prevention services (Table 7). 
 
Men Who Have Sex with Men (MSM) 
 
In 2012, 241,163 HIV testing events were conducted among MSM, with the majority in non-
health care settings (60.8%). Of the total HIV testing events among MSM, 7,481 (3.1%) 
were newly identified HIV-positive. Among tests conducted in health care settings (94,422), 
3.9% were newly identified HIV-positive and among those conducted in non-health care 
settings (146,639), 2.6% were newly identified HIV-positive. HIV positivity was higher for 
MSM tested in the U.S. dependent areas (6.1%) and in the South (4%), black/African 
American MSM (5.7%), and MSM aged 20-29 years (3.6%). Linkage to HIV medical care 
percentages among MSM varied by certain demographic characteristics (Table 12): 
 
• Persons aged 20-29 years: 42.1%–82.5% were linked within 90 days, and 56.5%–
71.6% were linked within any timeframe.  
 
• Black/African Americans: 40.1%–80.8% were linked within 90 days, and 52.4%–69% 
were linked within any timeframe. 
 
• South: 38.8%–83% were linked within 90 days, and 51.1%–67.1% were linked within 
any timeframe. 
 
• U.S. dependent areas: 81.4%–96.8% were linked within 90 days, and 82.7%–85% 
were linked within any timeframe. 
 
Heterosexual Females 
 
In 2012, 877,437 HIV testing events were conducted among heterosexual females, and of 
these, 2,202 (0.3%) were newly identified HIV-positive heterosexual females.  
 
HIV positivity percentage was higher for females tested in the U.S. dependent areas (0.8%), 
females aged 50 years and older (0.7%), females aged 40-49 years (0.6%), and 
black/African American females (0.4%). Linkage to HIV medical care percentages among 
heterosexual females varied by certain demographic characteristics (Table 14): 
 
• Females aged 40-49 years: 41%–78.9% were linked within 90 days, and 53.5%–
69.3% were linked within any timeframe. 
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• Females aged 50 years and older: 48.8%–83% were linked within 90 days, and 
59.6%–72.2% were linked within any timeframe. 
 
• Black/African Americans: 38.5%–80.7% were linked within 90 days, and 51.1%–
69.4% were linked within any timeframe. 
 
• U.S. dependent areas: 85.2%–96.8% were linked within 90 days, and 85.2%–92% 
were linked within any timeframe. 
Conclusions  
 
Significant changes were made to the 2012 annual HIV testing report in order to align with 
programmatic priorities for CDC-funded HIV testing programs. This report focuses on all newly 
identified HIV-positive persons, rather than only on newly identified confirmed HIV-positive 
persons.  
 
In February 2013, a joint letter from CDC and HRSA emphasized that all persons identified as 
HIV-positive should be linked to HIV medical care, regardless of whether they had received a 
preliminary or confirmed HIV-positive test result. Since the advent of treatment as prevention, 
timely linkage to HIV medical care has increasingly become a programmatic priority to ensure 
better health outcomes for HIV-positive persons and to prevent HIV transmission to HIV-
negative persons. Although identification of new HIV-positive persons is critical, ensuring that 
all HIV-positive persons receive necessary HIV prevention, care, and treatment services is 
equally important. Monitoring and evaluation data quality improvements are needed to more 
effectively track progress toward the goals outlined by NHAS and the DHAP Strategic Plan. 
 
The need to decrease missing/invalid data continues. Missing/invalid data result from 
jurisdictions not collecting or documenting all required data elements or reporting invalid value 
codes for required data elements. Missing/invalid data percentages varied widely by indicator. 
Receipt of HIV result had the least missing/invalid data (7%), followed by referral to partner 
services (19%), linkage to HIV medical care within any timeframe (24%), and referral to HIV 
prevention services (30%). Linkage to HIV medical care within 90 days had the highest 
percentage of missing/invalid data (56%) (Tables 4 and 5). Without complete data, it is 
difficult to monitor and evaluate CDC-funded HIV testing program progress toward key NHAS 
and DHAP targets. Jurisdictions should continue to strive to submit complete data to CDC’s 
NHM&E system so that CDC-funded HIV programs can be effectively monitored and evaluated.  
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Technical Notes 
National HIV Prevention Monitoring and Evaluation HIV Testing Data Collection 
 
The 2012 National HIV Prevention Monitoring and Evaluation (NHM&E) HIV testing data were 
submitted to CDC by health department and community-based organization (CBO) grantees 
through EvaluationWeb. Health departments and CBOs are required to submit data a minimum 
of twice annually (March and September). This report includes all testing events occurring in 
2012 that were reported to CDC by October 7, 2013. 
 
NHM&E data are submitted to CDC in a standard format. A data collection template including 
required data fields is provided to all jurisdictions. Health departments and CBOs are able to 
modify this template to better meet their local programmatic needs; however, required data 
fields cannot be omitted.  
 
Data Quality Assurance Monitoring and Grantee Feedback 
 
The Testing Monitoring and Evaluation Team (TMET) of the Program Evaluation Branch (PEB) in 
the Division of HIV/AIDS Prevention (DHAP) is tasked with ensuring the quality of the NHM&E 
HIV testing data. To meet this goal, a standardized, robust, data quality check is performed bi-
annually after each data submission deadline. Required data fields are checked to ensure 
minimal missing/invalid data. Additional attention is paid to required data fields used in the 
calculation of indicators, including HIV test result received, linkage to HIV medical care within 
any timeframe, linkage to HIV medical care within 90 days, referral to partner services, 
interview for partner services, and referral to HIV prevention services. TMET staff review the 
quality of the data with each health department jurisdiction to allow for discussion of any areas 
for improvement, and to instruct on high-priority data fields requiring edits or updates. 
 
Additionally, grantees are encouraged to develop and use local data quality assurance protocols 
and procedures to improve and maintain high-quality data. As required in CDC program 
announcements that support HIV testing activities, all CDC grantees must put in place 
processes to ensure programmatic quality (e.g., providing HIV test results to persons promptly 
and linking HIV-positive persons to HIV medical care).  
 
Interpretation of HIV Testing Data 
 
When interpreting data in this report, several points should be considered. 
  
• Significant changes were made to the calculations of the HIV testing indicators from 
previous reports. Therefore, comparability with previous annual HIV testing reports on 
several indicators is limited. Table 16 shows the number and percentages for HIV testing 
events, HIV-positive testing events, newly identified HIV-positive persons, and linkage to 
HIV medical care within any time frame by demographic characteristics from 2010-2012. 
This table applies the new calculations to each of the indicators for years 2010-2012. 
These changes will be described further in the next section, “Definitions.” 
 
• Some findings may be influenced by whether HIV testing sites more commonly promoted 
routine or targeted HIV testing. For example, the number of HIV testing events may be 
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lower in geographic areas or jurisdictions with targeted testing focused on certain high-
risk populations, and correspondingly, the HIV positivity in these areas or jurisdictions 
may be higher.  
 
• The population accessing HIV testing services at publicly-funded sites is not necessarily 
representative of all persons who are tested in the United States. This report does not 
include information about HIV testing services that were supported by the Departments 
of Defense, Justice, Labor, and Veterans Affairs, Centers for Medicare and Medicaid 
Services, Health Resources and Services Administration, Substance Abuse and Mental 
Health Services Administration, agencies of the U.S. Public Health Service other than 
CDC, state and local health departments, and the private sector. However, it is possible 
that some of these testing events may be included, if they were not categorized under 
the correct funding announcement when the data were submitted to CDC.  
 
• It is not possible to link the results of repeat HIV testing events for the same person in 
the same year. However, for persons who are newly identified HIV-positive, this is 
limited because those with a current HIV-positive test result and self-report of a previous 
HIV-positive test result are excluded.   
  
• HIV testing data are collected for HIV prevention program activities in conjunction with a 
health service delivery. Therefore, the comparability of these data across health 
department jurisdictions may be limited due to differences in data collection, quality 
assurance, or quality improvement activities that occur at the state or local levels. 
Comparability within a health department jurisdiction may also be limited for the same 
reasons.  
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Definitions 
 
Age 
 
The age of the person at testing, as determined by calculating the difference between the 
year of a person’s birth and the year of the HIV testing session. 
 
Data designation 
 
Aggregate data 
Total HIV testing events and confirmed HIV-positive testing events reported by health 
department jurisdictions when complete test-level data were not submitted to CDC.  
 
Invalid data 
Any test-level data submitted by the health department jurisdiction that do not 
conform to the value codes stated in the NHM&E data variable set (DVS).  
 
Missing data 
Any required data associated with a valid HIV testing record for which data were not 
submitted by the health department jurisdiction. These data were either not collected 
by the health department jurisdiction or were collected but not reported to CDC. 
 
Test-event level data 
Data reported by health department jurisdictions for each HIV testing event conducted, 
including demographics, HIV testing event data, and when appropriate, behavioral risk, 
linkage to HIV medical care (within 90 days and within any timeframe), referral to and 
interview for partner services and referral to HIV prevention services data. For this 
report, test-event–level data were reported for 59 health department jurisdictions. 
 
Data variable set  
 
Data dictionary with all NHM&E data elements, including mandatory, required, and allowed 
data elements. Information provided in the DVS includes variable number, name, schema 
name, format type, minimum and maximum length, value codes, instructions, and 
definitions.  
 
Gender 
 
The person’s self-reported current gender identity and may include one’s social status, self-
identification, legal status, and biology. Current gender identity is submitted to CDC as 
male, female, male-to-female transgender (i.e., a person whose physical or birth sex is 
male, but whose gender expression and/or gender identity is female), or female-to-male 
transgender (i.e., a person whose physical or birth sex is female, but whose gender 
expression and/or gender identity is male). Additionally, in order to identify transgender 
persons, sex at birth and current gender identity are examined. If the self-reported genders 
do not match, the person is classified as a transgender person.  
 
For this report, gender is reported as male or female. Transgender persons are reported 
under target populations (defined later in this section). 
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Interview for partner services 
 
Partner services include a range of available services for newly and previously diagnosed 
HIV-positive persons, their partners, and affected communities. Services may include: 
informing current and past sex partners that a person who is HIV-positive has identified 
them as a sex or injection-drug-paraphernalia-sharing partner and advising them to have 
HIV counseling and testing. Additionally, it can include notifying partners, who may not 
have suspected that they were at increased risk for HIV so that they can be tested for HIV. 
 
This calculated indicator measures the extent to which newly identified HIV-positive persons 
were interviewed for partner services. For this report, the minimum percentage includes 
missing/invalid data in the denominator and includes all newly identified HIV-positive 
persons. The maximum percentage excludes missing/invalid data from the denominator.  
 
Linkage to HIV medical care within 90 days 
 
HIV medical care includes medical services for HIV infection, including evaluation of immune 
system function and screening, treatment, and prevention of opportunistic infections. 
Because of the importance of linking HIV-positive persons to HIV medical care in a timely 
manner, this indicator is examined separately from “linkage to HIV medical care within any 
timeframe.”  
 
This calculated indicator measures the extent to which newly identified HIV-positive persons 
were linked to HIV medical care within 90 days after diagnosis. In order for a person to be 
linked to care, the person must have attended the first medical care appointment within 90 
days after the initial HIV testing session. For this report, the minimum percentage includes 
missing/invalid data in the denominator and includes all newly identified HIV-positive 
persons. The maximum percentage excludes missing/invalid data from the denominator.  
 
Linkage to HIV medical care within any timeframe 
 
HIV medical care includes medical services for HIV infection, including evaluation of immune 
system function and screening, treatment, and prevention of opportunistic infections. 
 
This calculated indicator measures the extent to which newly identified HIV-positive persons 
were linked to HIV medical care. In order for a person to be considered linked to HIV 
medical care within any timeframe, the person must have attended the first medical care 
appointment, regardless of when the appointment occurred. Linkage to HIV medical care 
within any timeframe includes persons who were linked within 90 days as well those who 
were linked after the 90-day period. For this report, the minimum percentage includes 
missing/invalid data in the denominator and includes all newly identified HIV-positive 
persons. The maximum percentage excludes missing/invalid data from the denominator.  
 
Race/ethnicity 
 
Race is defined as a person’s self-reported classification of the biological heritage with which 
they most closely identify. Ethnicity is defined as a person’s self-report of whether they are 
Hispanic or Latino. Up to five races and one ethnicity (i.e., Hispanic or Latino) for a person 
are allowed and submitted to CDC as separate variables. For this report, a “race/ethnicity” 
variable was created by combining the race and ethnicity variables using the following 
categories: 
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• Hispanic or Latino (“Hispanic or Latino” in the ethnicity variable regardless of the race 
variables) 
• Remaining persons who selected “Not Hispanic or Latino” for the ethnicity variable 
were categorized as: 
• White  
• Black or African American 
• Asian 
• American Indian or Alaska Native 
• Native Hawaiian or Pacific Islander 
• Multi-race (persons who selected more than one race) 
• Declined 
• Don’t know 
• Invalid 
• Missing 
 
Rapid test used in testing event  
 
This calculated variable indicates whether rapid testing technology was used for an HIV test. 
A response of “yes” indicates that at least one test within a testing event was performed by 
using a rapid test technology.  
  
Referral to HIV prevention services 
 
HIV prevention services are defined as any service or intervention directly aimed at 
reducing the risk of transmitting or acquiring HIV infection (e.g., prevention counseling, 
diffusion of effective behavioral interventions, risk-reduction counseling). HIV posttest 
counseling and indirect services, such as mental health services or housing, are excluded. 
 
This calculated indicator measures the extent to which newly identified HIV-positive persons 
were provided with a referral to HIV prevention services. For this report, the minimum 
percentage includes missing/invalid data in the denominator and includes all newly 
identified HIV-positive persons. The maximum percentage excludes missing/invalid data 
from the denominator.  
 
Referral to partner services 
 
Partner services include a range of available services for newly and previously diagnosed 
HIV-positive persons, their partners, and affected communities. Services may include 
informing current and past sex partners that a person who is HIV-positive has identified 
them as a sex or injection-drug-paraphernalia-sharing partner and advising them to have 
HIV counseling and testing. Additionally, it can include notifying partners, who may not 
have suspected that they were at increased risk of HIV so that they can be tested for HIV. 
 
This calculated indicator measures the extent to which newly identified HIV-positive persons 
were provided with a referral to partner services. For this report, the minimum percentage 
includes missing/invalid data in the denominator and includes all newly identified HIV-
positive persons. The maximum percentage excludes missing/invalid data from the 
denominator.  
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Results received 
 
This calculated indicator measures the extent to which persons received HIV test results 
from the initial testing site or obtained the results from another agency for at least one HIV 
test in the testing event, regardless of the HIV test technology or how many tests were 
conducted. For this report, the minimum percentage includes missing/invalid data in the 
denominator and includes all newly identified HIV-positive persons. The maximum 
percentage excludes missing/invalid data from the denominator.  
 
Target populations 
 
NHM&E data for target populations are collected from the person for behavior during the 12 
months before the HIV test. The collection of these data is required for all tests performed 
in non-health care settings and for HIV-positive persons in health care settings. For this 
report, mutually exclusive target populations are determined for HIV-positive persons by 
using a combination of behaviors and gender of the person (male, female, and 
transgender). The behaviors used to calculate the target populations include vaginal or anal 
sex with males or females and use of injection drugs. 
 
The target populations are ordered hierarchically on the basis of the most likely presumed 
risk for exposure to HIV as follows: 
 
• Men who have sex with men and report injection drug use: includes males who 
reported both male-to-male sexual contact and injection drug use in the past 12 
months 
 
• Men who have sex with men: includes males who reported male-to-male sexual 
contact in the past 12 months 
 
• Transgender persons who report injection drug use: includes transgender persons 
(i.e., self-reported sex at birth is different from self-reported current gender) who 
reported injection drug use in the past 12 months 
 
• Transgender person: includes persons whose self-reported gender at birth is different 
from self-reported current gender 
 
• Injection drug use: includes persons who reported injection drug use in the past 12 
months 
 
• Heterosexual male: includes males who only reported heterosexual contact with a 
female in the past 12 months 
 
• Heterosexual female: includes females who only reported heterosexual contact with a 
male in the past 12 months 
 
• Missing/invalid: includes persons: (1) who did not report any of these behaviors, (2) 
who were not asked about these behaviors, (3) who declined to discuss these 
behaviors, or (4) for whom these data were not reported, even though they were 
asked about these behaviors 
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Testing events 
 
HIV testing event 
An HIV testing event is one or more HIV tests performed with a person to determine a 
person’s HIV status. During one testing event, a person may be tested once (e.g., one 
rapid test or one conventional test) or multiple times (e.g., one rapid test followed by 
one conventional test to confirm a preliminary HIV-positive test result).  
 
Invalid HIV testing event 
An HIV testing event is considered invalid if data are missing/invalid for all of the tests 
that comprise that HIV testing event for both the following variables: test technology 
(i.e., conventional, rapid, or other) or HIV test result (i.e., negative, positive, 
indeterminate, invalid, or no result). These records (0.47% of the total records for 
2012) are not included in this report.  
 
Testing record 
 
Invalid testing record 
Required data within a valid HIV testing record that do not conform to the data 
structure specified by CDC (e.g., illogical dates (02/30/2012), incomplete dates 
(02/2012), future years, unacceptable value codes, or unexpected data based upon 
skip patterns in the data collection form). 
 
Valid HIV testing record 
A test-level data record that includes the mandatory data fields of: session date, 
agency ID, intervention ID, site ID, site type, and client ID. A test-level testing record 
cannot be submitted without the mandatory data fields. 
 
Test results  
 
Confirmed HIV-positive testing event 
A testing event with an HIV-positive test result for a conventional HIV test 
(positive enzyme immunoassay (EIA) test confirmed by supplemental testing, e.g., 
Western blot) or a nucleic acid amplification test (NAAT). For the purposes of the 2012 
annual HIV testing report and for monitoring and evaluation purposes only, two rapid 
tests were categorized as a confirmed HIV-positive testing event, unless a negative 
conventional HIV test result or a negative NAAT test result was documented in the 
same test event. 
 
HIV-positive testing event 
An HIV-positive testing event is determined by any of the following test results: (1) a 
NAAT/RNA positive test result, (2) a conventional positive test result if a negative 
NAAT/RNA test result was not part of that testing event, (3) a rapid positive test result 
if a negative NAAT/RNA or negative conventional test result was not part of that testing 
event, and (4) a documented positive test result, even if test technology data are 
missing/invalid if a negative NAAT/RNA or negative conventional test result was not 
part of that testing event. 
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Newly identified HIV-positive person  
An HIV-positive test result associated with a person who reports: (1) no previous HIV 
test, (2) a previous HIV test with a negative or an indeterminate result, or (3) “don’t 
know” for previous HIV test result.  
 
Preliminary HIV-positive testing event 
A testing event with an HIV-positive test result from one rapid HIV test or an HIV-
positive test result for which test technology is missing/invalid, without another 
documented HIV-positive test result. 
 
Previous HIV-positive person 
A person who self-reports having a previous positive HIV test result. 
 
Test setting 
  
Test setting is determined by the site type where HIV testing is provided, and for this 
report, it is classified into the following categories: 
 
• Health care and correctional facilities: inpatient facilities, outpatient facilities, 
emergency rooms, and correctional facilities 
 
• Non-healthcare facilities: HIV counseling and testing sites and community settings 
 
• Other facilities: blood banks/plasma centers and any other facilities not previously 
listed 
 
• Invalid: the site code submitted for the facility is not one of the acceptable site 
codes 
 
• Missing: no site code is submitted for the testing event 
 
U.S. geographic region 
   
The U.S. geographic regions are as follows: 
 
• Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New 
York, Pennsylvania, Rhode Island, and Vermont 
 
• Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, 
North Dakota, Ohio, South Dakota, and Wisconsin 
 
• South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, 
Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South 
Carolina, Tennessee, Texas, Virginia, and West Virginia 
 
• West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New 
Mexico, Oregon, Utah, Washington, and Wyoming 
 
• U.S. dependent areas: Puerto Rico and U.S. Virgin Islands 
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Figure 1. Newly identified HIV positivity percentages by characteristics of persons tested, 59 health department 
jurisdictions in the United States, Puerto Rico, and the U.S. Virgin Islands, 2012.  
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The percentage of newly identified HIV-positive persons in 
the 59 health department jurisdictions submitting test-
level NHM&E data in the United States, Puerto Rico, and 
the U.S. Virgin Islands in 2012 was 0.5% 
(16,976/3,287,024), as depicted by the dash line. 
 
Blue bars indicate demographic characteristics in which 
the HIV positivity percentage is greater than 0.5%. 
30-39 
40-49 
Multi-race 
Transgender 
Black/African American 
American Indian/Alaska Natives and Native Hawaiian/Pacific Islanders are omitted due to the small number of newly identified HIV-positive persons. 
Please refer to Tables 4 or 6 for figure data. 
29 
 
Figure 2. HIV testing and care continuum indicators among newly identfied HIV-positive persons, 59 health 
department jurisdictions in the United States, Puerto Rico, and the U. S. Virgin Islands, 2012. 
 
 
Minimum: 52.2% 
Minimum: 34.1% 
Minimum: 65.7% 
Minimum: 51.3% 
Minimum: 36% 
Linkage to HIV medical care within 90 days (maximum): 82.2% 
Linkage to HIV medical care within any timeframe (maximum): 67.1% 
Referral to partner services (maximum): 81.1% 
Interview for partner services (maximum): 60.7% 
Referral to HIV prevention services (maximum): 74.1% 
Maximum indicator percentages exclude missing data from the denominator.  Minimum percentages include missing data in the denominator.  Please refer to 
Tables 4-7 for figure data.  Note:  The maximum percentage for linkage to HIV medical care within 90 days is greater than the maximum percentage for linkage 
within any timeframe due to the higher percentage of missing/invalid data for linkage within 90 days. 
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Figure 3. HIV testing and care continuum indicators among newly identfied HIV-positive men who have sex with 
men (MSM), 59 health department jurisdictions in the United States, Puerto Rico, and the U. S. Virgin Islands, 2012.  
 
  
Minimum: 63.4% 
Minimum: 41.8% 
Minimum: 77.7% 
Minimum: 58.2% 
Minimum: 44.5% 
Linkage to HIV medical care within90 days (maximum): 84.8% 
Linkage to HIV medical care within any timeframe (maximum): 72.6% 
Referral to partner services (maximum): 86% 
Interview for partner services (maximum): 67.2% 
Referral to HIV prevention services (maximum): 78.6% 
Maximum indicator percentages exclude missing data from the denominator.  Minimum percentages include missing data in the denominator.  Please refer to 
Tables 12-13 for figure data.  Note:  The maximum percentage for linkage to HIV medical care within 90 days is greater than the maximum percentage for linkage 
within any timeframe due to the higher percentage of missing/invalid data for linkage within 90 days. 
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Figure 4. HIV testing and care continuum indicators among newly identfied HIV-positive heterosexual women, 59 
health department jurisdictions in the United States, Puerto Rico, and the U. S. Virgin Islands, 2012. 
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Linkage to HIV medical care within 90 days (maximum): 81.7% 
Linkage to HIV medical care within any timeframe (maximum): 70.3% 
Referral to partner services (maximum): 82.2% 
Interview for partner services (maximum): 63.2% 
Referral to HIV prevention services (maximum): 76.4% 
Maximum indicator percentages exclude missing data from the denominator.  Minimum percentages include missing data in the denominator.  Please refer to 
Tables 14-15 for figure data.  Note:  The maximum percentage for linkage to HIV medical care within 90 days is greater than the maximum percentage for linkage 
within any timeframe due to the higher percentage of missing/invalid data for linkage within 90 days. 
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Table 1. Number of HIV testing events and HIV positivity by 61 CDC-funded jurisdictions, United States, 
Puerto Rico, and the U.S. Virgin Islands, 2012. 
CDC-funded jurisdiction 
HIV 
testing 
events 
HIV-positive 
testing 
events 
Preliminary HIV-
positive testing 
events 
Confirmed HIV-
positive 
testing events 
Newly identified 
confirmed HIV-positive 
persons 
No. No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) No. (Positive %) 
Alabama 100,182 587 (0.6) 24 (0.0) 563 (0.6) 197 (0.2) 
Alaska 2,690 7 (0.3) 2 (0.1) 5 (0.2) 3 (0.1) 
Arizona 26,438 294 (1.1) 46 (0.2) 248 (0.9) 162 (0.6) 
Arkansas 49,222 599 (1.2) 44 (0.1) 555 (1.1) 543 (1.1) 
California          
   Los Angeles 116,585 1,301 (1.1) 273 (0.2) 1,028 (0.9) 815 (0.7) 
   San Francisco 47,824 685 (1.4) 23 (0.0) 662 (1.4) 246 (0.5) 
   California (excludes Los Angeles  
and San Francisco) 
91,893 541 (0.6) 102 (0.1) 439 (0.5) 351 (0.4) 
Colorado 11,405 145 (1.3) 1 (0.0) 144 (1.3) 103 (0.9) 
Connecticut 26,805 85 (0.3) 17 (0.1) 68 (0.3) 59 (0.2) 
Delaware 10,856 56 (0.5) 3 (0.0) 53 (0.5) 44 (0.4) 
District of Columbia 113,789 844 (0.7) 651 (0.6) 193 (0.2) 180 (0.2) 
Florida 407,086 4,393 (1.1) 380 (0.1) 4,013 (1.0) 2,319 (0.6) 
Georgia          
   Atlantaa 41,960 … … … … 781 (1.9) … … 
   Georgia (excludes Atlanta) 86,053 501 (0.6) 70 (0.1) 431 (0.5) 343 (0.4) 
Hawaii 6,930 26 (0.4) 4 (0.1) 22 (0.3) 22 (0.3) 
Idaho 4,564 21 (0.5) 10 (0.2) 11 (0.2) 9 (0.2) 
Illinois          
   Chicago 64,261 594 (0.9) 206 (0.3) 388 (0.6) 221 (0.3) 
   Illinois (excludes Chicago) 6,239 107 (1.7) 12 (0.2) 95 (1.5) 87 (1.4) 
Indiana 14,329 111 (0.8) 14 (0.1) 97 (0.7) 90 (0.6) 
Iowa 5,695 33 (0.6) 0 (0.0) 33 (0.6) 29 (0.5) 
Kansas 28,240 91 (0.3) 0 (0.0) 91 (0.3) 73 (0.3) 
Kentucky 28,251 141 (0.5) 62 (0.2) 79 (0.3) 69 (0.2) 
Louisiana 97,476 1,050 (1.1) 39 (0.0) 1,011 (1.0) 253 (0.3) 
Maine 3,631 12 (0.3) 0 (0.0) 12 (0.3) 8 (0.2) 
Maryland          
   Baltimore 46,106 499 (1.1) 32 (0.1) 467 (1.0) 359 (0.8) 
   Maryland (excludes Baltimore) 57,844 423 (0.7) 184 (0.3) 239 (0.4) 182 (0.3) 
Massachusetts 66,458 391 (0.6) 167 (0.3) 224 (0.3) 76 (0.1) 
Michiganb 75,040 … … … … 418 (0.6) … … 
Minnesota 13,828 142 (1.0) 40 (0.3) 102 (0.7) 95 (0.7) 
Mississippi 83,319 885 (1.1) 65 (0.1) 820 (1.0) 380 (0.5) 
Missouri 88,514 596 (0.7) 45 (0.1) 551 (0.6) 161 (0.2) 
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CDC-funded jurisdiction 
HIV 
testing 
events 
HIV-positive 
testing 
events 
Preliminary HIV-
positive testing 
events 
Confirmed HIV-
positive 
testing events 
Newly identified 
confirmed HIV-positive 
persons 
No. No. 
(Positive 
%) No. 
(Positive 
%) No. 
(Positive 
%) No. (Positive %) 
Montana 2,189 6 (0.3) 3 (0.1) 3 (0.1) 3 (0.1) 
Nebraska 9,732 23 (0.2) 10 (0.1) 13 (0.1) 11 (0.1) 
Nevada 21,685 254 (1.2) 11 (0.1) 243 (1.1) 175 (0.8) 
New Hampshire 1,081 7 (0.6) 0 (0.0) 7 (0.6) 7 (0.6) 
New Jersey 66,884 498 (0.7) 124 (0.2) 374 (0.6) 291 (0.4) 
New Mexico 7,481 66 (0.9) 7 (0.1) 59 (0.8) 44 (0.6) 
New York          
   New York City 114,316 718 (0.6) 129 (0.1) 589 (0.5) 500 (0.4) 
   New York (excludes New York City) 185,726 1,058 (0.6) 125 (0.1) 933 (0.5) 587 (0.3) 
North Carolina 212,537 802 (0.4) 0 (0.0) 802 (0.4) 537 (0.3) 
North Dakota 3,442 2 (0.1) 0 (0.0) 2 (0.1) 2 (0.1) 
Ohio 60,549 445 (0.7) 128 (0.2) 317 (0.5) 271 (0.4) 
Oklahoma 21,660 180 (0.8) 33 (0.2) 147 (0.7) 109 (0.5) 
Oregonb 10,824 … … … … 67 (0.6) … … 
Pennsylvania          
   Philadelphia 81,746 542 (0.7) 89 (0.1) 453 (0.6) 326 (0.4) 
   Pennsylvania (excludes Philadelphia) 85,353 422 (0.5) 33 (0.0) 389 (0.5) 240 (0.3) 
Rhode Island 2,178 18 (0.8) 10 (0.5) 8 (0.4) 5 (0.2) 
South Carolina 80,074 723 (0.9) 143 (0.2) 580 (0.7) 103 (0.1) 
South Dakota 1,240 3 (0.2) 0 (0.0) 3 (0.2) 3 (0.2) 
Tennessee 145,867 1,220 (0.8) 117 (0.1) 1,103 (0.8) 744 (0.5) 
Texas          
   Houston 70,133 1,138 (1.6) 56 (0.1) 1,082 (1.5) 111 (0.2) 
   Texas (excludes Houston) 214,617 2,060 (1.0) 170 (0.1) 1,890 (0.9) 1,254 (0.6) 
Utah 7,863 58 (0.7) 27 (0.3) 31 (0.4) 30 (0.4) 
Vermont 3,079 5 (0.2) 2 (0.1) 3 (0.1) 3 (0.1) 
Virginia 69,814 315 (0.5) 25 (0.0) 290 (0.4) 232 (0.3) 
Washington 15,186 240 (1.6) 22 (0.1) 218 (1.4) 127 (0.8) 
West Virginia 5,111 18 (0.4) 1 (0.0) 17 (0.3) 11 (0.2) 
Wisconsin 14,240 106 (0.7) 12 (0.1) 94 (0.7) 87 (0.6) 
Wyoming 4,024 9 (0.2) 5 (0.1) 4 (0.1) 0 (0.0) 
Puerto Rico 33,291 598 (1.8) 27 (0.1) 571 (1.7) 461 (1.4) 
U.S. Virgin Islands 3,717 2 (0.1) 1 (0.0) 1 (0.0) 1 (0.0) 
Total 3,379,152 26,696 (0.8) 3,826 (0.1) 24,136 (0.7) 13,754 (0.4) 
a Data from Atlanta were reported at the aggregate level only for Table 1, which added 6,246 testing events but excluded 929 HIV-positive testing 
events, 130 preliminary HIV-positive testing events, 18 confirmed HIV-positive testing events, and 512 newly identified confirmed HIV-positive persons 
that are included in the remaining tables, which display test-level data. 
b Data from Michigan and Oregon are reported at the aggregate level and are therefore only reported in Table 1.  As a result, the number of HIV 
testing events and confirmed HIV-positive testing events are higher in Table 1 and are reflected in the totals.  The tables that follow exclude data 
from Michigan and Oregon and only report test-level data.
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Table 2. Number of HIV testing events and newly identified HIV positivity percentages by test setting for 59 
CDC-funded health department jurisdictions submitting test-level data in the United States, Puerto Rico, 
and the U.S. Virgin Islands, 2012. 
CDC-funded jurisdiction 
Health care and correctional facilities Non-health care facilities 
HIV testing events 
Newly identified HIV-
positive persons HIV testing events 
Newly identified HIV-
positive persons 
No. (%) No. 
(New 
positive 
%) No. (%) No. 
(New 
positive 
%) 
Alabama 76,546 (76.4) 173 (0.2) 23,636 (23.6) 30 (0.1) 
Alaska 225 (8.4) 2 (0.9) 2,465 (91.6) 2 (0.1) 
Arizona 13,404 (50.7) 117 (0.9) 13,034 (49.3) 76 (0.6) 
Arkansas 45,566 (92.6) 517 (1.1) 3,656 (7.4) 63 (1.7) 
California         
   Los Angeles 68,495 (58.8) 519 (0.8) 48,090 (41.2) 510 (1.1) 
   San Francisco 29,259 (61.2) 57 (0.2) 18,432 (38.5) 202 (1.1) 
   California (excludes Los Angeles  
 and San Francisco) 
71,708 (78.0) 305 (0.4) 19,703 (21.4) 111 (0.6) 
Colorado 8,120 (71.2) 50 (0.6) 3,285 (28.8) 54 (1.6) 
Connecticut 13,641 (50.9) 32 (0.2) 13,164 (49.1) 36 (0.3) 
Delaware 6,568 (60.5) 26 (0.4) 4,288 (39.5) 19 (0.4) 
District of Columbia 109,595 (96.3) 589 (0.5) 4,194 (3.7) 70 (1.7) 
Florida 246,842 (60.6) 1,217 (0.5) 160,235 (39.4) 1,374 (0.9) 
Georgia         
   Atlanta 21,399 (59.9) 222 (1.0) 14,210 (39.8) 379 (2.7) 
   Georgia (excludes Atlanta) 78,181 (90.9) 296 (0.4) 7,872 (9.1) 97 (1.2) 
Hawaii 3,202 (46.2) 5 (0.2) 3,728 (53.8) 20 (0.5) 
Idaho 2,179 (47.7) 11 (0.5) 2,385 (52.3) 4 (0.2) 
Illinois         
   Chicago 50,977 (79.3) 225 (0.4) 13,284 (20.7) 147 (1.1) 
   Illinois (excludes Chicago) 2,042 (32.7) 32 (1.6) 4,197 (67.3) 67 (1.6) 
Indiana 8,156 (56.9) 36 (0.4) 6,173 (43.1) 67 (1.1) 
Iowa 4,198 (73.7) 18 (0.4) 1,497 (26.3) 11 (0.7) 
Kansas 25,518 (90.4) 47 (0.2) 2,722 (9.6) 26 (1.0) 
Kentucky 23,767 (84.1) 95 (0.4) 4,484 (15.9) 33 (0.7) 
Louisiana 65,743 (67.4) 122 (0.2) 31,733 (32.6) 150 (0.5) 
Maine 1,575 (43.4) 4 (0.3) 2,056 (56.6) 4 (0.2) 
Maryland         
   Baltimore 32,832 (71.2) 193 (0.6) 13,274 (28.8) 188 (1.4) 
   Maryland (excludes Baltimore) 31,689 (54.8) 165 (0.5) 26,151 (45.2) 121 (0.5) 
Massachusetts 47,814 (71.9) 92 (0.2) 18,644 (28.1) 30 (0.2) 
Minnesota 10,567 (76.4) 107 (1.0) 3,261 (23.6) 20 (0.6) 
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CDC-funded jurisdiction 
Health care and correctional facilities Non-health care facilities 
HIV testing events 
Newly identified HIV-
positive persons HIV testing events 
Newly identified HIV-
positive persons 
No. (%) No. 
(New 
positive 
%) No. (%) No. 
(New 
positive 
%) 
Mississippi 72,512 (87.0) 389 (0.5) 10,807 (13.0) 24 (0.2) 
Missouri 76,345 (86.3) 101 (0.1) 12,169 (13.7) 82 (0.7) 
Montana 482 (22.0) 0 (0.0) 1,707 (78.0) 4 (0.2) 
Nebraska 7,418 (76.2) 10 (0.1) 2,314 (23.8) 8 (0.3) 
Nevada 12,934 (59.6) 99 (0.8) 8,751 (40.4) 85 (1.0) 
New Hampshire 1,065 (98.5) 7 (0.7) 16 (1.5) 0 (0.0) 
New Jersey 48,434 (72.4) 208 (0.4) 18,444 (27.6) 179 (1.0) 
New Mexico 4,060 (54.3) 32 (0.8) 3,421 (45.7) 18 (0.5) 
New York         
   New York City 66,394 (58.1) 270 (0.4) 47,922 (41.9) 323 (0.7) 
   New York (excludes New York City) 83,115 (44.8) 420 (0.5) 102,144 (55.0) 242 (0.2) 
North Carolina 114,330 (53.8) 187 (0.2) 97,851 (46.0) 347 (0.4) 
North Dakota 2,555 (74.2) 0 (0.0) 887 (25.8) 2 (0.2) 
Ohio 43,957 (72.6) 276 (0.6) 16,592 (27.4) 104 (0.6) 
Oklahoma 16,159 (74.6) 47 (0.3) 5,501 (25.4) 91 (1.7) 
Pennsylvania         
   Philadelphia 72,111 (88.2) 226 (0.3) 9,635 (11.8) 161 (1.7) 
   Pennsylvania (excludes Philadelphia) 68,024 (79.7) 172 (0.3) 15,638 (18.3) 84 (0.5) 
Rhode Island 457 (21.0) 5 (1.1) 1,679 (77.1) 10 (0.6) 
South Carolina 70,673 (88.3) 95 (0.1) 8,844 (11.0) 105 (1.2) 
South Dakota 505 (40.7) 1 (0.2) 735 (59.3) 2 (0.3) 
Tennessee 125,418 (86.0) 738 (0.6) 20,449 (14.0) 101 (0.5) 
Texas         
   Houston 65,093 (92.8) 35 (0.1) 5,040 (7.2) 119 (2.4) 
   Texas (excludes Houston) 133,904 (62.4) 693 (0.5) 80,635 (37.6) 642 (0.8) 
Utah 4,851 (61.7) 35 (0.7) 3,012 (38.3) 17 (0.6) 
Vermont 2,230 (72.4) 4 (0.2) 849 (27.6) 1 (0.1) 
Virginia 58,198 (83.4) 166 (0.3) 11,616 (16.6) 90 (0.8) 
Washington 5,800 (38.2) 57 (1.0) 9,386 (61.8) 79 (0.8) 
West Virginia 3,583 (70.1) 7 (0.2) 1,528 (29.9) 5 (0.3) 
Wisconsin 6,534 (45.9) 25 (0.4) 7,706 (54.1) 70 (0.9) 
Wyoming 3,808 (94.6) 0 (0.0) 216 (5.4) 0 (0.0) 
Puerto Rico 24,497 (73.6) 414 (1.7) 8,794 (26.4) 69 (0.8) 
U.S. Virgin Islands 2,247 (60.5) 1 (0.0) 1,470 (39.5) 1 (0.1) 
Total 2,297,501 (69.9) 9,994 (0.4) 985,611 (30.0) 6,976 (0.7) 
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Table 3. HIV testing and care continuum for persons identified as previously HIV-positive for 59 health department jurisdictions 
providing test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2012. 
CDC-funded jurisdiction 
HIV 
testing 
events 
Previous HIV-
positive 
persons 
Already in 
HIV medical 
care Linkage to HIV medical care within any medical timeframea Linkage to HIV medical care in 90 daysa,b 
All testing 
events No. 
(Positive 
%) No. 
(% in 
care) Linked 
Not 
linked 
Missing
/invalid 
Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing
/invalid 
(Missing  
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Alabama 100,182 235 (0.2) 0 (0.0) 0 0 235 (100.0) (0.0) (0.0) 0 0 235 (100.0) (0.0) (0.0) 
Alaska 2,690 2 (0.1) 0 (0.0) 1 0 1 (50.0) (50.0) (100.0) 1 0 1 (50.0) (50.0) (100.0) 
Arizona 26,438 73 (0.3) 1 (1.4) 66 5 1 (1.4) (91.7) (93.0) 0 1 71 (98.6) (0.0) (0.0) 
Arkansas 49,222 13 (0.0) 1 (7.7) 3 2 7 (58.3) (25.0) (60.0) 1 1 10 (83.3) (8.3) (50.0) 
California                  
   Los Angeles 116,585 253 (0.2) 15 (5.9) 177 25 36 (15.1) (74.4) (87.6) 97 9 132 (55.5) (40.8) (91.5) 
   San Francisco 47,824 391 (0.8) 3 (0.8) 221 14 153 (39.4) (57.0) (94.0) 13 1 374 (96.4) (3.4) (92.9) 
   California (excludes Los 
Angeles and San 
Francisco) 
91,893 92 (0.1) 0 (0.0) 65 24 3 (3.3) (70.7) (73.0) 47 19 26 (28.3) (51.1) (71.2) 
Colorado 11,405 31 (0.3) 7 (22.6) 22 2 0 (0.0) (91.7) (91.7) 16 1 7 (29.2) (66.7) (94.1) 
Connecticut 26,805 13 (0.0) 0 (0.0) 6 6 1 (7.7) (46.2) (50.0) 4 1 8 (61.5) (30.8) (80.0) 
Delaware 10,856 11 (0.1) 2 (18.2) 8 1 0 (0.0) (88.9) (88.9) 8 0 1 (11.1) (88.9) (100.0) 
District of Columbia 113,789 136 (0.1) 29 (21.3) 41 25 41 (38.3) (38.3) (62.1) 26 17 64 (59.8) (24.3) (60.5) 
Florida 407,086 1,598 (0.4) 0 (0.0) 1,255 330 13 (0.8) (78.5) (79.2) 1,190 84 324 (20.3) (74.5) (93.4) 
Georgia                  
   Atlanta 35,696 321 (0.9) 6 (1.9) 199 97 19 (6.0) (63.2) (67.2) 188 81 46 (14.6) (59.7) (69.9) 
   Georgia (excludes Atlanta) 86,053 103 (0.1) 10 (9.7) 49 11 33 (35.5) (52.7) (81.7) 42 8 43 (46.2) (45.2) (84.0) 
Hawaii 6,930 1 (0.0) 1 (100.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
Idaho 4,564 3 (0.1) 2 (66.7) 1 0 0 (0.0) (100.0) (100.0) 1 0 0 (0.0) (100.0) (100.0) 
Illinois                  
   Chicago 64,261 116 (0.2) 38 (32.8) 25 5 48 (61.5) (32.1) (83.3) 25 2 51 (65.4) (32.1) (92.6) 
   Illinois (excludes Chicago) 6,239 6 (0.1) 0 (0.0) 0 5 1 (16.7) (0.0) (0.0) 0 0 6 (100.0) (0.0) (0.0) 
Indiana 14,329 7 (0.0) 1 (14.3) 1 1 4 (66.7) (16.7) (50.0) 1 2 3 (50.0) (16.7) (33.3) 
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CDC-funded jurisdiction 
HIV 
testing 
events 
Previous HIV-
positive 
persons 
Already in 
HIV medical 
care Linkage to HIV medical care within any medical timeframea Linkage to HIV medical care in 90 daysa,b 
All testing 
events No. 
(Positive 
%) No. 
(% in 
care) Linked 
Not 
linked 
Missing
/invalid 
Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing
/invalid 
(Missing  
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Iowa 5,695 2 (0.0) 0 (0.0) 2 0 0 (0.0) (100.0) (100.0) 2 0 0 (0.0) (100.0) (100.0) 
Kansas 28,240 18 (0.1) 1 (5.6) 7 5 5 (29.4) (41.2) (58.3) 3 2 12 (70.6) (17.6) (60.0) 
Kentucky 28,251 13 (0.0) 0 (0.0) 6 2 5 (38.5) (46.2) (75.0) 6 0 7 (53.8) (46.2) (100.0) 
Louisiana 97,476 142 (0.1) 0 (0.0) 117 24 1 (0.7) (82.4) (83.0) 0 24 118 (83.1) (0.0) (0.0) 
Maine 3,631 3 (0.1) 0 (0.0) 3 0 0 (0.0) (100.0) (100.0) 2 1 0 (0.0) (66.7) (66.7) 
Maryland                  
   Baltimore 46,106 110 (0.2) 71 (64.5) 28 7 4 (10.3) (71.8) (80.0) 25 2 12 (30.8) (64.1) (92.6) 
Maryland (excludes 
Baltimore) 
57,844 126 (0.2) 38 (30.2) 57 22 9 (10.2) (64.8) (72.2) 27 22 39 (44.3) (30.7) (55.1) 
Massachusetts 66,458 247 (0.4) 11 (4.5) 92 116 28 (11.9) (39.0) (44.2) 92 0 144 (61.0) (39.0) (100.0) 
Minnesota 13,828 15 (0.1) 0 (0.0) 5 7 3 (20.0) (33.3) (41.7) 4 1 10 (66.7) (26.7) (80.0) 
Mississippi 83,319 470 (0.6) 110 (23.4) 194 13 153 (42.5) (53.9) (93.7) 191 4 165 (45.8) (53.1) (97.9) 
Missouri 88,514 85 (0.1) 15 (17.6) 55 15 0 (0.0) (78.6) (78.6) 51 12 7 (10.0) (72.9) (81.0) 
Montana 2,189 2 (0.1) 0 (0.0) 1 0 1 (50.0) (50.0) (100.0) 1 0 1 (50.0) (50.0) (100.0) 
Nebraska 9,732 2 (0.0) 1 (50.0) 1 0 0 (0.0) (100.0) (100.0) 1 0 0 (0.0) (100.0) (100.0) 
Nevada 21,685 60 (0.3) 4 (6.7) 47 8 1 (1.8) (83.9) (85.5) 47 3 6 (10.7) (83.9) (94.0) 
New Hampshire 1,081 0 (0.0) 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
New Jersey 66,884 108 (0.2) 8 (7.4) 73 21 6 (6.0) (73.0) (77.7) 69 10 21 (21.0) (69.0) (87.3) 
New Mexico 7,481 14 (0.2) 1 (7.1) 9 3 1 (7.7) (69.2) (75.0) 9 0 4 (30.8) (69.2) (100.0) 
New York                  
   New York City 114,316 98 (0.1) 9 (9.2) 48 23 18 (20.2) (53.9) (67.6) 11 7 71 (79.8) (12.4) (61.1) 
   New York (excludes New 
York City) 
185,726 373 (0.2) 0 (0.0) 323 3 47 (12.6) (86.6) (99.1) 239 48 86 (23.1) (64.1) (83.3) 
North Carolina 212,537 210 (0.1) 0 (0.0) 0 0 210 (100.0) (0.0) (0.0) 0 0 210 (100.0) (0.0) (0.0) 
North Dakota 3,442 0 (0.0) 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
Ohio 60,549 65 (0.1) 3 (4.6) 27 8 27 (43.5) (43.5) (77.1) 10 3 49 (79.0) (16.1) (76.9) 
Oklahoma 21,660 42 (0.2) 4 (9.5) 7 31 0 (0.0) (18.4) (18.4) 6 0 32 (84.2) (15.8) (100.0) 
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CDC-funded jurisdiction 
HIV 
testing 
events 
Previous HIV-
positive 
persons 
Already in 
HIV medical 
care Linkage to HIV medical care within any medical timeframea Linkage to HIV medical care in 90 daysa,b 
All testing 
events No. 
(Positive 
%) No. 
(% in 
care) Linked 
Not 
linked 
Missing
/invalid 
Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing
/invalid 
(Missing  
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Pennsylvania                  
   Philadelphia 81,746 84 (0.1) 5 (6.0) 31 34 14 (17.7) (39.2) (47.7) 26 11 42 (53.2) (32.9) (70.3) 
   Pennsylvania (excludes 
Philadelphia) 
85,353 89 (0.1) 7 (7.9) 25 21 36 (43.9) (30.5) (54.3) 18 2 62 (75.6) (22.0) (90.0) 
Rhode Island 2,178 3 (0.1) 0 (0.0) 2 1 0 (0.0) (66.7) (66.7) 2 0 1 (33.3) (66.7) (100.0) 
South Carolina 80,074 81 (0.1) 22 (27.2) 38 11 10 (16.9) (64.4) (77.6) 31 11 17 (28.8) (52.5) (73.8) 
South Dakota 1,240 0 (0.0) 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
Tennessee 145,867 370 (0.3) 24 (6.5) 42 35 269 (77.7) (12.1) (54.5) 5 19 322 (93.1) (1.4) (20.8) 
Texas                  
   Houston 70,133 801 (1.1) 26 (3.2) 186 21 568 (73.3) (24.0) (89.9) 140 53 582 (75.1) (18.1) (72.5) 
   Texas (excludes Houston) 214,617 723 (0.3) 0 (0.0) 435 149 139 (19.2) (60.2) (74.5) 36 5 682 (94.3) (5.0) (87.8) 
Utah 7,863 6 (0.1) 2 (33.3) 1 0 3 (75.0) (25.0) (100.0) 1 0 3 (75.0) (25.0) (100.0) 
Vermont 3,079 0 (0.0) 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
Virginia 69,814 51 (0.1) 4 (7.8) 34 3 10 (21.3) (72.3) (91.9) 6 2 39 (83.0) (12.8) (75.0) 
Washington 15,186 104 (0.7) 13 (12.5) 73 13 5 (5.5) (80.2) (84.9) 73 4 14 (15.4) (80.2) (94.8) 
West Virginia 5,111 5 (0.1) 1 (20.0) 2 1 1 (25.0) (50.0) (66.7) 0 0 4 (100.0) (0.0) (0.0) 
Wisconsin 14,240 8 (0.1) 4 (50.0) 3 0 1 (25.0) (75.0) (100.0) 3 0 1 (25.0) (75.0) (100.0) 
Wyoming 4,024 0 (0.0) 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
Puerto Rico 33,291 113 (0.3) 46 (40.7) 42 12 13 (19.4) (62.7) (77.8) 41 6 20 (29.9) (61.2) (87.2) 
U.S. Virgin Islands 3,717 0 (0.0) 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
Total 3,287,024 8,048 (0.2) 546 (6.8) 4,156 1,162 2,184 (29.1) (55.4) (78.1) 2,838 479 4,185 (55.8) (37.8) (85.6) 
 
a Persons who reported already being in HIV medical care were excluded from the denominator for both linkage indicators. 
b Linkage to HIV medical care within 90 days was not collected in the 2008-2011 version of the HIV testing form.  Although this is a required reporting indicator for 2012, data for 13.2% of previous HIV-
positive persons in 2012 were reported using the previous version of the testing form.  Therefore, these data are represented as missing/invalid data.    
  
 
 
 
 
40 
 
Table 4. HIV testing and care continuum, including HIV positivity and linkage to care, for newly identified HIV-positive persons from 
59 health department jurisdictions providing test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2012. 
CDC-funded jurisdiction 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positives 
(New 
positive 
%) Linked 
Not 
linked 
Missing
/invalid 
(Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Alabama 100,182 203 (0.2) 0 0 203 (100.0) (0.0) (0.0) 0 0 203 (100.0) (0.0) (0.0) 
Alaska 2,690 4 (0.1) 2 2 0 (0.0) (50.0) (50.0) 2 1 1 (25.0) (50.0) (66.7) 
Arizona 26,438 193 (0.7) 136 33 24 (12.4) (70.5) (80.5) 0 9 184 (95.3) (0.0) (0.0) 
Arkansas 49,222 580 (1.2) 11 420 149 (25.7) (1.9) (2.6) 2 1 577 (99.5) (0.3) (66.7) 
California                
   Los Angeles 116,585 1,029 (0.9) 599 142 288 (28.0) (58.2) (80.8) 287 30 712 (69.2) (27.9) (90.5) 
   San Francisco 47,824 261 (0.5) 131 88 42 (16.1) (50.2) (59.8) 95 2 164 (62.8) (36.4) (97.9) 
   California (excludes Los  
Angeles and San Francisco) 
91,893 416 (0.5) 308 102 6 (1.4) (74.0) (75.1) 251 47 118 (28.4) (60.3) (84.2) 
Colorado 11,405 104 (0.9) 99 5 0 (0.0) (95.2) (95.2) 89 6 9 (8.7) (85.6) (93.7) 
Connecticut 26,805 68 (0.3) 37 19 12 (17.6) (54.4) (66.1) 32 3 33 (48.5) (47.1) (91.4) 
Delaware 10,856 45 (0.4) 37 7 1 (2.2) (82.2) (84.1) 36 4 5 (11.1) (80.0) (90.0) 
District of Columbia 113,789 659 (0.6) 342 143 174 (26.4) (51.9) (70.5) 231 58 370 (56.1) (35.1) (79.9) 
Florida 407,086 2,591 (0.6) 1,681 750 160 (6.2) (64.9) (69.1) 1,573 170 848 (32.7) (60.7) (90.2) 
Georgia                
   Atlanta 35,696 602 (1.7) 314 207 81 (13.5) (52.2) (60.3) 289 95 218 (36.2) (48.0) (75.3) 
   Georgia (excludes Atlanta) 86,053 393 (0.5) 188 73 132 (33.6) (47.8) (72.0) 142 35 216 (55.0) (36.1) (80.2) 
Hawaii 6,930 25 (0.4) 17 5 3 (12.0) (68.0) (77.3) 17 0 8 (32.0) (68.0) (100.0) 
Idaho 4,564 15 (0.3) 6 1 8 (53.3) (40.0) (85.7) 5 0 10 (66.7) (33.3) (100.0) 
Illinois                
   Chicago 64,261 372 (0.6) 157 39 176 (47.3) (42.2) (80.1) 155 17 200 (53.8) (41.7) (90.1) 
   Illinois (excludes Chicago) 6,239 99 (1.6) 6 23 70 (70.7) (6.1) (20.7) 5 3 91 (91.9) (5.1) (62.5) 
Indiana 14,329 103 (0.7) 24 21 58 (56.3) (23.3) (53.3) 24 48 31 (30.1) (23.3) (33.3) 
Iowa 5,695 29 (0.5) 16 3 10 (34.5) (55.2) (84.2) 16 2 11 (37.9) (55.2) (88.9) 
Kansas 28,240 73 (0.3) 41 13 19 (26.0) (56.2) (75.9) 39 2 32 (43.8) (53.4) (95.1) 
Kentucky 28,251 128 (0.5) 20 54 54 (42.2) (15.6) (27.0) 18 1 109 (85.2) (14.1) (94.7) 
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CDC-funded jurisdiction 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positives 
(New 
positive 
%) Linked 
Not 
linked 
Missing
/invalid 
(Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Louisiana 97,476 272 (0.3) 179 74 19 (7.0) (65.8) (70.8) 0 74 198 (72.8) (0.0) (0.0) 
Maine 3,631 8 (0.2) 7 1 0 (0.0) (87.5) (87.5) 7 1 0 (0.0) (87.5) (87.5) 
Maryland                
   Baltimore 46,106 381 (0.8) 176 185 20 (5.2) (46.2) (48.8) 166 78 137 (36.0) (43.6) (68.0) 
   Maryland (excludes Baltimore) 57,844 286 (0.5) 107 127 52 (18.2) (37.4) (45.7) 80 71 135 (47.2) (28.0) (53.0) 
Massachusetts 66,458 122 (0.2) 53 54 15 (12.3) (43.4) (49.5) 53 0 69 (56.6) (43.4) (100.0) 
Minnesota 13,828 127 (0.9) 51 41 35 (27.6) (40.2) (55.4) 50 14 63 (49.6) (39.4) (78.1) 
Mississippi 83,319 413 (0.5) 253 5 155 (37.5) (61.3) (98.1) 251 1 161 (39.0) (60.8) (99.6) 
Missouri 88,514 183 (0.2) 136 41 6 (3.3) (74.3) (76.8) 126 40 17 (9.3) (68.9) (75.9) 
Montana 2,189 4 (0.2) 3 1 0 (0.0) (75.0) (75.0) 3 0 1 (25.0) (75.0) (100.0) 
Nebraska 9,732 18 (0.2) 12 2 4 (22.2) (66.7) (85.7) 7 1 10 (55.6) (38.9) (87.5) 
Nevada 21,685 184 (0.8) 126 53 5 (2.7) (68.5) (70.4) 124 9 51 (27.7) (67.4) (93.2) 
New Hampshire 1,081 7 (0.6) 5 0 2 (28.6) (71.4) (100.0) 5 0 2 (28.6) (71.4) (100.0) 
New Jersey 66,884 387 (0.6) 205 127 55 (14.2) (53.0) (61.7) 175 33 179 (46.3) (45.2) (84.1) 
New Mexico 7,481 50 (0.7) 29 17 4 (8.0) (58.0) (63.0) 23 6 21 (42.0) (46.0) (79.3) 
New York                
   New York City 114,316 593 (0.5) 369 113 111 (18.7) (62.2) (76.6) 179 68 346 (58.3) (30.2) (72.5) 
   New York (excludes New York 
City) 
185,726 662 (0.4) 553 7 102 (15.4) (83.5) (98.8) 435 89 138 (20.8) (65.7) (83.0) 
North Carolina 212,537 537 (0.3) 0 0 537 (100.0) (0.0) (0.0) 0 0 537 (100.0) (0.0) (0.0) 
North Dakota 3,442 2 (0.1) 2 0 0 (0.0) (100.0) (100.0) 2 0 0 (0.0) (100.0) (100.0) 
Ohio 60,549 380 (0.6) 214 82 84 (22.1) (56.3) (72.3) 114 31 235 (61.8) (30.0) (78.6) 
Oklahoma 21,660 138 (0.6) 17 121 0 (0.0) (12.3) (12.3) 11 6 121 (87.7) (8.0) (64.7) 
Pennsylvania                
   Philadelphia 81,746 387 (0.5) 214 130 43 (11.1) (55.3) (62.2) 171 66 150 (38.8) (44.2) (72.2) 
   Pennsylvania (excludes 
Philadelphia) 
85,353 256 (0.3) 81 74 101 (39.5) (31.6) (52.3) 39 10 207 (80.9) (15.2) (79.6) 
Rhode Island 2,178 15 (0.7) 9 3 3 (20.0) (60.0) (75.0) 5 0 10 (66.7) (33.3) (100.0) 
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CDC-funded jurisdiction 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positives 
(New 
positive 
%) Linked 
Not 
linked 
Missing
/invalid 
(Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
South Carolina 80,074 200 (0.2) 98 51 51 (25.5) (49.0) (65.8) 85 20 95 (47.5) (42.5) (81.0) 
South Dakota 1,240 3 (0.2) 2 0 1 (33.3) (66.7) (100.0) 2 0 1 (33.3) (66.7) (100.0) 
Tennessee 145,867 839 (0.6) 220 242 377 (44.9) (26.2) (47.6) 52 113 674 (80.3) (6.2) (31.5) 
Texas                
   Houston 70,133 154 (0.2) 8 41 105 (68.2) (5.2) (16.3) 8 1 145 (94.2) (5.2) (88.9) 
   Texas (excludes Houston) 214,617 1,335 (0.6) 667 359 309 (23.1) (50.0) (65.0) 28 5 1,302 (97.5) (2.1) (84.8) 
Utah 7,863 52 (0.7) 22 6 24 (46.2) (42.3) (78.6) 18 2 32 (61.5) (34.6) (90.0) 
Vermont 3,079 5 (0.2) 2 1 2 (40.0) (40.0) (66.7) 2 0 3 (60.0) (40.0) (100.0) 
Virginia 69,814 256 (0.4) 139 45 72 (28.1) (54.3) (75.5) 29 19 208 (81.3) (11.3) (60.4) 
Washington 15,186 136 (0.9) 99 23 14 (10.3) (72.8) (81.1) 96 11 29 (21.3) (70.6) (89.7) 
West Virginia 5,111 12 (0.2) 5 2 5 (41.7) (41.7) (71.4) 0 0 12 (100.0) (0.0) (0.0) 
Wisconsin 14,240 95 (0.7) 69 17 9 (9.5) (72.6) (80.2) 69 1 25 (26.3) (72.6) (98.6) 
Wyomingb 4,024 0 .... …. …. …. .... .... .... …. …. …. .... .... .... 
Puerto Rico 33,291 483 (1.5) 397 64 22 (4.6) (82.2) (86.1) 393 18 72 (14.9) (81.4) (95.6) 
U.S. Virgin Islands 3,717 2 (0.1) 1 0 1 (50.0) (50.0) (100.0) 1 0 1 (50.0) (50.0) (100.0) 
Total 3,287,024 16,976 (0.5) 8,702 4,259 4,015 (23.7) (51.3) (67.1) 6,117 1,322 9,537 (56.2) (36.0) (82.2) 
 
a Linkage to HIV medical care within 90 days was not collected in the 2008-2011 version of the HIV testing form.  Although this is a required reporting indicator for 2012, data for 15.6% of newly identified       
HIV-positive persons in 2012 were reported using the previous version of the testing form.  Therefore, these data are represented as missing/invalid data.    
       b No new HIV-positive persons were identified in Wyoming.  Therefore, linkage data are not applicable. 
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Table 5.  HIV testing and care continuum, including partner and HIV prevention services, for newly identified HIV-positive persons 
from 59 health department jurisdictions providing test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2012. 
CDC-funded  
Jurisdiction 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Alabama 2 1 200 (98.5) (1.0) (66.7) 0 1 202 (99.5) (0.0) (0.0) 3 0 200 (98.5) (1.5) (100.0) 
Alaska 4 0 0 (0.0) (100.0) (100.0) 4 0 0 (0.0) (100.0) (100.0) 1 3 0 (0.0) (25.0) (25.0) 
Arizona 161 12 20 (10.4) (83.4) (93.1) 125 17 51 (26.4) (64.8) (88.0) 103 40 50 (25.9) (53.4) (72.0) 
Arkansas 154 425 1 (0.2) (26.6) (26.6) 3 425 152 (26.2) (0.5) (0.7) 8 423 149 (25.7) (1.4) (1.9) 
California                   
   Los Angeles 736 27 266 (25.9) (71.5) (96.5) 0 47 982 (95.4) (0.0) (0.0) 552 158 319 (31.0) (53.6) (77.7) 
   San 
Francisco 
184 17 60 (23.0) (70.5) (91.5) 38 28 195 (74.7) (14.6) (57.6) 237 16 8 (3.1) (90.8) (93.7) 
   California   
(excludes Los 
Angeles / San 
Francisco) 
354 62 0 (0.0) (85.1) (85.1) 98 303 15 (3.6) (23.6) (24.4) 346 62 8 (1.9) (83.2) (84.8) 
Colorado 95 9 0 (0.0) (91.3) (91.3) 86 12 6 (5.8) (82.7) (87.8) 96 8 0 (0.0) (92.3) (92.3) 
Connecticut 55 10 3 (4.4) (80.9) (84.6) 32 20 16 (23.5) (47.1) (61.5) 53 12 3 (4.4) (77.9) (81.5) 
Delaware 41 4 0 (0.0) (91.1) (91.1) 33 4 8 (17.8) (73.3) (89.2) 13 32 0 (0.0) (28.9) (28.9) 
District of 
Columbia 
354 305 0 (0.0) (53.7) (53.7) 230 327 102 (15.5) (34.9) (41.3) 408 251 0 (0.0) (61.9) (61.9) 
Florida 2,352 15 224 (8.6) (90.8) (99.4) 1,999 442 150 (5.8) (77.2) (81.9) 1,701 463 427 (16.5) (65.7) (78.6) 
Georgia                   
   Atlanta 399 166 37 (6.1) (66.3) (70.6) 234 171 197 (32.7) (38.9) (57.8) 458 105 39 (6.5) (76.1) (81.3) 
   Georgia 
(excludes 
Atlanta) 
319 62 12 (3.1) (81.2) (83.7) 214 90 89 (22.6) (54.5) (70.4) 310 70 13 (3.3) (78.9) (81.6) 
Hawaii 11 14 0 (0.0) (44.0) (44.0) 9 16 0 (0.0) (36.0) (36.0) 23 2 0 (0.0) (92.0) (92.0) 
Idaho 15 0 0 (0.0) (100.0) (100.0) 9 0 6 (40.0) (60.0) (100.0) 11 4 0 (0.0) (73.3) (73.3) 
Illinois                   
   Chicago 204 37 131 (35.2) (54.8) (84.6) 35 39 298 (80.1) (9.4) (47.3) 167 13 192 (51.6) (44.9) (92.8) 
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CDC-funded  
Jurisdiction 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
   Illinois 
(excludes 
Chicago) 
85 14 0 (0.0) (85.9) (85.9) 72 27 0 (0.0) (72.7) (72.7) 69 22 8 (8.1) (69.7) (75.8) 
Indiana 59 13 31 (30.1) (57.3) (81.9) 0 13 90 (87.4) (0.0) (0.0) 28 44 31 (30.1) (27.2) (38.9) 
Iowa 23 2 4 (13.8) (79.3) (92.0) 20 2 7 (24.1) (69.0) (90.9) 23 2 4 (13.8) (79.3) (92.0) 
Kansas 72 1 0 (0.0) (98.6) (98.6) 70 3 0 (0.0) (95.9) (95.9) 53 20 0 (0.0) (72.6) (72.6) 
Kentucky 90 30 8 (6.3) (70.3) (75.0) 57 35 36 (28.1) (44.5) (62.0) 92 24 12 (9.4) (71.9) (79.3) 
Louisiana 161 76 35 (12.9) (59.2) (67.9) 0 76 196 (72.1) (0.0) (0.0) 27 1 244 (89.7) (9.9) (96.4) 
Maine 8 0 0 (0.0) (100.0) (100.0) 6 1 1 (12.5) (75.0) (85.7) 7 0 1 (12.5) (87.5) (100.0) 
Maryland                   
   Baltimore 205 133 43 (11.3) (53.8) (60.7) 154 189 38 (10.0) (40.4) (44.9) 88 0 293 (76.9) (23.1) (100.0) 
   Maryland 
(excludes 
Baltimore) 
165 63 58 (20.3) (57.7) (72.4) 105 112 69 (24.1) (36.7) (48.4) 64 0 222 (77.6) (22.4) (100.0) 
Massachusetts 59 46 17 (13.9) (48.4) (56.2) 25 72 25 (20.5) (20.5) (25.8) 0 0 122 (100.0) (0.0) (0.0) 
Minnesota 110 14 3 (2.4) (86.6) (88.7) 77 22 28 (22.0) (60.6) (77.8) 119 6 2 (1.6) (93.7) (95.2) 
Mississippi 260 1 152 (36.8) (63.0) (99.6) 94 1 318 (77.0) (22.8) (98.9) 255 2 156 (37.8) (61.7) (99.2) 
Missouri 163 20 0 (0.0) (89.1) (89.1) 140 41 2 (1.1) (76.5) (77.3) 163 20 0 (0.0) (89.1) (89.1) 
Montana 4 0 0 (0.0) (100.0) (100.0) 1 0 3 (75.0) (25.0) (100.0) 4 0 0 (0.0) (100.0) (100.0) 
Nebraska 16 1 1 (5.6) (88.9) (94.1) 5 1 12 (66.7) (27.8) (83.3) 17 0 1 (5.6) (94.4) (100.0) 
Nevada 140 40 4 (2.2) (76.1) (77.8) 125 45 14 (7.6) (67.9) (73.5) 131 46 7 (3.8) (71.2) (74.0) 
New 
Hampshire 
7 0 0 (0.0) (100.0) (100.0) 7 0 0 (0.0) (100.0) (100.0) 7 0 0 (0.0) (100.0) (100.0) 
New Jersey 92 262 33 (8.5) (23.8) (26.0) 49 272 66 (17.1) (12.7) (15.3) 156 204 27 (7.0) (40.3) (43.3) 
New Mexico 41 9 0 (0.0) (82.0) (82.0) 33 12 5 (10.0) (66.0) (73.3) 28 21 1 (2.0) (56.0) (57.1) 
New York                   
   New York 
City 
358 84 151 (25.5) (60.4) (81.0) 155 95 343 (57.8) (26.1) (62.0) 261 82 250 (42.2) (44.0) (76.1) 
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CDC-funded  
Jurisdiction 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
   New York 
(excludes New 
York City) 
476 101 85 (12.8) (71.9) (82.5) 0 101 561 (84.7) (0.0) (0.0) 469 107 86 (13.0) (70.8) (81.4) 
North Carolina 537 0 0 (0.0) (100.0) (100.0) 0 0 537 (100.0) (0.0) (0.0) 0 0 537 (100.0) (0.0) (0.0) 
North Dakota 2 0 0 (0.0) (100.0) (100.0) 2 0 0 (0.0) (100.0) (100.0) 2 0 0 (0.0) (100.0) (100.0) 
Ohio 336 27 17 (4.5) (88.4) (92.6) 173 31 176 (46.3) (45.5) (84.8) 335 27 18 (4.7) (88.2) (92.5) 
Oklahoma 72 66 0 (0.0) (52.2) (52.2) 30 66 42 (30.4) (21.7) (31.3) 70 68 0 (0.0) (50.7) (50.7) 
Pennsylvania                   
   Philadelphia 249 134 4 (1.0) (64.3) (65.0) 106 218 63 (16.3) (27.4) (32.7) 264 109 14 (3.6) (68.2) (70.8) 
  Pennsylvania 
(excludes 
Philadelphia) 
99 61 96 (37.5) (38.7) (61.9) 58 62 136 (53.1) (22.7) (48.3) 118 76 62 (24.2) (46.1) (60.8) 
Rhode Island 7 5 3 (20.0) (46.7) (58.3) 2 6 7 (46.7) (13.3) (25.0) 5 8 2 (13.3) (33.3) (38.5) 
South Carolina 161 18 21 (10.5) (80.5) (89.9) 127 30 43 (21.5) (63.5) (80.9) 99 78 23 (11.5) (49.5) (55.9) 
South Dakota 3 0 0 (0.0) (100.0) (100.0) 1 0 2 (66.7) (33.3) (100.0) 1 2 0 (0.0) (33.3) (33.3) 
Tennessee 462 51 326 (38.9) (55.1) (90.1) 31 53 755 (90.0) (3.7) (36.9) 469 45 325 (38.7) (55.9) (91.2) 
Texas                   
   Houston 129 5 20 (13.0) (83.8) (96.3) 103 21 30 (19.5) (66.9) (83.1) 133 1 20 (13.0) (86.4) (99.3) 
   Texas 
(excludes 
Houston) 
176 59 1,100 (82.4) (13.2) (74.9) 162 63 1,110 (83.1) (12.1) (72.0) 126 110 1,099 (82.3) (9.4) (53.4) 
Utah 30 0 22 (42.3) (57.7) (100.0) 26 0 26 (50.0) (50.0) (100.0) 30 0 22 (42.3) (57.7) (100.0) 
Vermont 2 2 1 (20.0) (40.0) (50.0) 0 3 2 (40.0) (0.0) (0.0) 3 1 1 (20.0) (60.0) (75.0) 
Virginia 214 30 12 (4.7) (83.6) (87.7) 29 30 197 (77.0) (11.3) (49.2) 184 62 10 (3.9) (71.9) (74.8) 
Washington 126 6 4 (2.9) (92.6) (95.5) 108 19 9 (6.6) (79.4) (85.0) 36 97 3 (2.2) (26.5) (27.1) 
West Virginia 7 3 2 (16.7) (58.3) (70.0) 0 3 9 (75.0) (0.0) (0.0) 8 2 2 (16.7) (66.7) (80.0) 
Wisconsin 80 14 1 (1.1) (84.2) (85.1) 68 19 8 (8.4) (71.6) (78.2) 56 38 1 (1.1) (58.9) (59.6) 
Puerto Rico 431 49 3 (0.6) (89.2) (89.8) 410 60 13 (2.7) (84.9) (87.2) 374 106 3 (0.6) (77.4) (77.9) 
U.S. Virgin 
Islands 
1 0 1 (50.0) (50.0) (100.0) 1 0 1 (50.0) (50.0) (100.0) 1 0 1 (50.0) (50.0) (100.0) 
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CDC-funded  
Jurisdiction 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Total 11,158 2,606 3,212 (18.9) (65.7) (81.1) 5,781 3,746 7,449 (43.9) (34.1) (60.7) 8,865 3,093 5,018 (29.6) (52.2) (74.1) 
 
a Interview for partner services was not collected in the 2008-2011 version of the HIV testing form.  Therefore, these data are represented as missing/invalid data. 
Note:  No new HIV-positive persons were identified in Wyoming so Wyoming is not included in this table, as partner services and prevention services data are not applicable. 
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Table 6.  HIV testing and care continuum of testing events, including HIV positivity and linkage to care, by demographic 
characteristics of newly identified HIV-positive persons from 59 health department jurisdictions providing test-level data in the 
United States, Puerto Rico, and the U.S. Virgin Islands, 2012. 
Demographic characteristics 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positive 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Age at test (years)                
   <13 5,133 18 (0.4) 6 5 7 (38.9) (33.3) (54.5) 4 1 13 (72.2) (22.2) (80.0) 
   13–19 303,523 606 (0.2) 288 144 174 (28.7) (47.5) (66.7) 214 56 336 (55.4) (35.3) (79.3) 
   20–29 1,346,543 6,710 (0.5) 3,406 1,642 1,662 (24.8) (50.8) (67.5) 2,334 556 3,820 (56.9) (34.8) (80.8) 
   30–39 725,598 4,083 (0.6) 2,186 987 910 (22.3) (53.5) (68.9) 1,475 279 2,329 (57.0) (36.1) (84.1) 
   40–49 463,353 3,212 (0.7) 1,640 816 756 (23.5) (51.1) (66.8) 1,216 236 1,760 (54.8) (37.9) (83.7) 
   50+ 423,382 2,296 (0.5) 1,152 651 493 (21.5) (50.2) (63.9) 857 191 1,248 (54.4) (37.3) (81.8) 
  Missing/invalid 19,492 51 (0.3) 24 14 13 (25.5) (47.1) (63.2) 17 3 31 (60.8) (33.3) (85.0) 
Gender                
   Male 1,574,184 13,333 (0.8) 6,954 3,354 3,025 (22.7) (52.2) (67.5) 4,865 1,024 7,444 (55.8) (36.5) (82.6) 
   Female 1,679,449 3,304 (0.2) 1,591 825 888 (26.9) (48.2) (65.9) 1,158 265 1,881 (56.9) (35.0) (81.4) 
   Other 8,740 61 (0.7) 31 22 8 (13.1) (50.8) (58.5) 0 19 42 (68.9) (0.0) (0.0) 
   Declined/not asked 2,831 13 (0.5) 7 4 2 (15.4) (53.8) (63.6) 4 1 8 (61.5) (30.8) (80.0) 
  Missing/invalid 10,068 59 (0.6) 16 9 34 (57.6) (27.1) (64.0) 15 0 44 (74.6) (25.4) (100.0) 
Race/ethnicity                
   White 895,814 3,523 (0.4) 1,851 907 765 (21.7) (52.5) (67.1) 1,292 218 2,013 (57.1) (36.7) (85.6) 
   Black or African American 1,444,796 8,884 (0.6) 4,138 2,347 2,399 (27.0) (46.6) (63.8) 2,969 800 5,115 (57.6) (33.4) (78.8) 
   Hispanic or Latino 686,757 3,497 (0.5) 2,219 678 600 (17.2) (63.5) (76.6) 1,577 204 1,716 (49.1) (45.1) (88.5) 
   Asian 62,832 236 (0.4) 133 60 43 (18.2) (56.4) (68.9) 95 21 120 (50.8) (40.3) (81.9) 
   American Indian or Alaska 
Native 
16,566 87 (0.5) 33 31 23 (26.4) (37.9) (51.6) 22 9 56 (64.4) (25.3) (71.0) 
   Native Hawaiian or Pacific 
Islander 
8,148 41 (0.5) 24 8 9 (22.0) (58.5) (75.0) 17 2 22 (53.7) (41.5) (89.5) 
   Multi-race 22,413 149 (0.7) 88 38 23 (15.4) (59.1) (69.8) 62 12 75 (50.3) (41.6) (83.8) 
   Declined 52,456 187 (0.4) 113 59 15 (8.0) (60.4) (65.7) 20 46 121 (64.7) (10.7) (30.3) 
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Demographic characteristics 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positive 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
   Don't know/not asked 88,214 334 (0.4) 103 131 100 (29.9) (30.8) (44.0) 63 10 261 (78.1) (18.9) (86.3) 
   Missing/invalid 9,028 38 (0.4) 0 0 38 (100.0) (0.0) (0.0) 0 0 38 (100.0) (0.0) (0.0) 
Region                
   Northeast 637,257 2,510 (0.4) 1,535 529 446 (17.8) (61.2) (74.4) 1,103 270 1,137 (45.3) (43.9) (80.3) 
   Midwest 310,309 1,484 (0.5) 730 282 472 (31.8) (49.2) (72.1) 609 159 716 (48.2) (41.0) (79.3) 
   South 1,935,693 10,024 (0.5) 4,462 2,906 2,656 (26.5) (44.5) (60.6) 3,001 752 6,271 (62.6) (29.9) (80.0) 
   West 366,757 2,473 (0.7) 1,577 478 418 (16.9) (63.8) (76.7) 1,010 123 1,340 (54.2) (40.8) (89.1) 
   U.S. dependent areas 37,008 485 (1.3) 398 64 23 (4.7) (82.1) (86.1) 394 18 73 (15.1) (81.2) (95.6) 
Testing site type                
   Health care facilities including 
correctional facility clinics 
2,297,501 9,994 (0.4) 5,154 2,440 2,400 (24.0) (51.6) (67.9) 3,635 816 5,543 (55.5) (36.4) (81.7) 
   Non-health care facilities 985,611 6,976 (0.7) 3,547 1,817 1,612 (23.1) (50.8) (66.1) 2,481 506 3,989 (57.2) (35.6) (83.1) 
   Other facilities 2 0 (0.0) … … … … … … … … … … … … 
   Missing/invalid 3,910 6 (0.2) 1 2 3 (50.0) (16.7) (33.3) 1 0 5 (83.3) (16.7) (100.0) 
Target population (not required 
for persons who test negative in 
health care settings) 
               
   Men who have sex with men 
and injection drug use 
6,387 237 (3.7) 142 53 42 (17.7) (59.9) (72.8) 106 23 108 (45.6) (44.7) (82.2) 
   Men who have sex with men 234,776 7,244 (3.1) 4,209 1,587 1,448 (20.0) (58.1) (72.6) 3,224 572 3,448 (47.6) (44.5) (84.9) 
   Transgender and injection 
drug use 
515 16 (3.1) 7 2 7 (43.8) (43.8) (77.8) 4 1 11 (68.8) (25.0) (80.0) 
   Transgender 11,237 190 (1.7) 96 43 51 (26.8) (50.5) (69.1) 71 12 107 (56.3) (37.4) (85.5) 
   Injection drug use 76,408 373 (0.5) 145 130 98 (26.3) (38.9) (52.7) 111 47 215 (57.6) (29.8) (70.3) 
   Heterosexual males 609,741 2,557 (0.4) 1,267 645 645 (25.2) (49.6) (66.3) 975 276 1,306 (51.1) (38.1) (77.9) 
   Heterosexual females 877,437 2,202 (0.3) 1,172 495 535 (24.3) (53.2) (70.3) 904 203 1,095 (49.7) (41.1) (81.7) 
  Not asked/no 
risk/missing/invalidb 
1,470,523 4,157 (0.3) 1,664 1,304 1,189 (28.6) (40.0) (56.1) 722 188 3,247 (78.1) (17.4) (79.3) 
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Demographic characteristics 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positive 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Rapid test used in testing 
event 
               
   Yes 1,856,530 11,934 (0.6) 6,614 2,839 2,481 (20.8) (55.4) (70.0) 4,583 1,023 6,328 (53.0) (38.4) (81.8) 
   No 1,420,827 5,036 (0.4) 2,088 1,420 1,528 (30.3) (41.5) (59.5) 1,534 299 3,203 (63.6) (30.5) (83.7) 
  Missing/invalid 9,667 6 (0.1) 0 0 6 (100.0) (0.0) (0.0) 0 0 6 (100.0) (0.0) (0.0) 
Total 3,287,024 16,976 (0.5) 8,702 4,259 4,015 (23.7) (51.3) (67.1) 6,117 1,322 9,537 (56.2) (36.0) (82.2) 
       
 a Linkage to HIV medical care within 90 days was not collected in the 2008-2011 version of the HIV testing form.  Although this is a required reporting indicator for 2012, data for 15.6% of newly identified    
 HIV-positive persons in 2012 were reported using the previous version of the testing form.  Therefore, these data are represented as missing/invalid data. 
b Data to identify target populations are required for all testing events conducted in non-health care settings but are only required for HIV-positive persons from health care settings.   
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Table 7.  HIV testing and care continuum, including partner and HIV prevention services, by demographic characteristics of newly 
identified HIV-positive persons from 59 health department jurisdictions providing test-level data in the United States, Puerto Rico, 
and the U.S. Virgin Islands, 2012. 
Demographic 
characteristics 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Age at test (years)                   
   <13 9 8 1 (5.6) (50.0) (52.9) 4 8 6 (33.3) (22.2) (33.3) 7 7 4 (22.2) (38.9) (50.0) 
   13–19 422 82 102 (16.8) (69.6) (83.7) 225 118 263 (43.4) (37.1) (65.6) 314 91 201 (33.2) (51.8) (77.5) 
   20–29 4,594 882 1,234 (18.4) (68.5) (83.9) 2,363 1,277 3,070 (45.8) (35.2) (64.9) 3,573 1,151 1,986 (29.6) (53.2) (75.6) 
   30–39 2,665 616 802 (19.6) (65.3) (81.2) 1,366 891 1,826 (44.7) (33.5) (60.5) 2,147 777 1,159 (28.4) (52.6) (73.4) 
   40–49 2,045 548 619 (19.3) (63.7) (78.9) 1,046 790 1,376 (42.8) (32.6) (57.0) 1,657 595 960 (29.9) (51.6) (73.6) 
   50+ 1,389 462 445 (19.4) (60.5) (75.0) 753 649 894 (38.9) (32.8) (53.7) 1,144 459 693 (30.2) (49.8) (71.4) 
  Missing/invalid 34 8 9 (17.6) (66.7) (81.0) 24 13 14 (27.5) (47.1) (64.9) 23 13 15 (29.4) (45.1) (63.9) 
Gender                   
   Male 8,848 1,987 2,498 (18.7) (66.4) (81.7) 4,558 2,872 5,903 (44.3) (34.2) (61.3) 7,138 2,412 3,783 (28.4) (53.5) (74.7) 
   Female 2,049 574 681 (20.6) (62.0) (78.1) 1,102 804 1,398 (42.3) (33.4) (57.8) 1,571 584 1,149 (34.8) (47.5) (72.9) 
   Other 60 1 0 (0.0) (98.4) (98.4) 52 8 1 (1.6) (85.2) (86.7) 7 45 9 (14.8) (11.5) (13.5) 
   Declined/ 
not asked 
7 6 0 (0.0) (53.8) (53.8) 3 7 3 (23.1) (23.1) (30.0) 8 4 1 (7.7) (61.5) (66.7) 
  Missing/invalid 57 2 0 (0.0) (96.6) (96.6) 22 3 34 (57.6) (37.3) (88.0) 20 6 33 (55.9) (33.9) (76.9) 
Race/ethnicity                   
   White 2,376 501 646 (18.3) (67.4) (82.6) 1,234 762 1,527 (43.3) (35.0) (61.8) 2,020 697 806 (22.9) (57.3) (74.3) 
   Black or African 
American 
5,759 1,468 1,657 (18.7) (64.8) (79.7) 2,942 1,991 3,951 (44.5) (33.1) (59.6) 4,410 1,575 2,899 (32.6) (49.6) (73.7) 
   Hispanic or 
Latino 
2,395 391 711 (20.3) (68.5) (86.0) 1,382 678 1,437 (41.1) (39.5) (67.1) 2,008 583 906 (25.9) (57.4) (77.5) 
   Asian 160 31 45 (19.1) (67.8) (83.8) 50 61 125 (53.0) (21.2) (45.0) 139 43 54 (22.9) (58.9) (76.4) 
   American Indian 
or Alaska Native 
63 17 7 (8.0) (72.4) (78.8) 28 23 36 (41.4) (32.2) (54.9) 48 21 18 (20.7) (55.2) (69.6) 
   Native Hawaiian  
or Pacific Islander 
28 4 9 (22.0) (68.3) (87.5) 14 5 22 (53.7) (34.1) (73.7) 23 7 11 (26.8) (56.1) (76.7) 
   Multi-race 118 17 14 (9.4) (79.2) (87.4) 66 29 54 (36.2) (44.3) (69.5) 86 35 28 (18.8) (57.7) (71.1) 
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Demographic 
characteristics 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
   Declined 109 54 24 (12.8) (58.3) (66.9) 15 61 111 (59.4) (8.0) (19.7) 34 10 143 (76.5) (18.2) (77.3) 
   Don't know/not 
asked 
112 123 99 (29.6) (33.5) (47.7) 50 136 148 (44.3) (15.0) (26.9) 96 122 116 (34.7) (28.7) (44.0) 
   Missing/invalid 38 0 0 (0.0) (100.0) (100.0) 0 0 38 (100.0) (0.0) (0.0) 1 0 37 (97.4) (2.6) (100.0) 
Region                   
   Northeast 1,412 705 393 (15.7) (56.3) (66.7) 440 850 1,220 (48.6) (17.5) (34.1) 1,343 599 568 (22.6) (53.5) (69.2) 
   Midwest 1,153 143 188 (12.7) (77.7) (89.0) 663 198 623 (42.0) (44.7) (77.0) 1,033 194 257 (17.3) (69.6) (84.2) 
   South 6,260 1,513 2,251 (22.5) (62.5) (80.5) 3,605 2,139 4,280 (42.7) (36.0) (62.8) 4,516 1,737 3,771 (37.6) (45.1) (72.2) 
   West 1,901 196 376 (15.2) (76.9) (90.7) 662 499 1,312 (53.1) (26.8) (57.0) 1,598 457 418 (16.9) (64.6) (77.8) 
   U.S. dependent 
areas 
432 49 4 (0.8) (89.1) (89.8) 411 60 14 (2.9) (84.7) (87.3) 375 106 4 (0.8) (77.3) (78.0) 
Testing site type                   
   Health care 
facilities includes 
correctional 
facility clinics 
6,581 1,464 1,949 (19.5) (65.8) (81.8) 3,539 2,041 4,414 (44.2) (35.4) (63.4) 5,304 1,906 2,784 (27.9) (53.1) (73.6) 
Non-health care 
facilities 
4,574 1,139 1,263 (18.1) (65.6) (80.1) 2,242 1,702 3,032 (43.5) (32.1) (56.8) 3,561 1,184 2,231 (32.0) (51.0) (75.0) 
   Missing/invalid 3 3 0 (0.0) (50.0) (50.0) 0 3 3 (50.0) (0.0) (0.0) 0 3 3 (50.0) (0.0) (0.0) 
Target population 
(not required for 
persons who test 
negative in health 
care settings) 
                  
Men who have 
sex with men,  
injection drug use 
167 33 37 (15.6) (70.5) (83.5) 85 62 90 (38.0) (35.9) (57.8) 136 52 49 (20.7) (57.4) (72.3) 
Men who have 
sex with men 
5,644 912 688 (9.5) (77.9) (86.1) 3,039 1,463 2,742 (37.9) (42.0) (67.5) 4,605 1,241 1,398 (19.3) (63.6) (78.8) 
   Transgender and 
injection drug use 
12 1 3 (18.8) (75.0) (92.3) 1 3 12 (75.0) (6.3) (25.0) 10 2 4 (25.0) (62.5) (83.3) 
   Transgender 125 35 30 (15.8) (65.8) (78.1) 43 49 98 (51.6) (22.6) (46.7) 111 40 39 (20.5) (58.4) (73.5) 
   Injection drug use 191 93 89 (23.9) (51.2) (67.3) 96 138 139 (37.3) (25.7) (41.0) 184 61 128 (34.3) (49.3) (75.1) 
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Demographic 
characteristics 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
   Heterosexual 
males 
1,786 399 372 (14.5) (69.8) (81.7) 957 580 1,020 (39.9) (37.4) (62.3) 1,335 420 802 (31.4) (52.2) (76.1) 
   Heterosexual 
females 
1,575 341 286 (13.0) (71.5) (82.2) 872 508 822 (37.3) (39.6) (63.2) 1,201 370 631 (28.7) (54.5) (76.4) 
   Not asked/no 
risk/missing/ 
invalid 
1,658 792 1,707 (41.1) (39.9) (67.7) 688 943 2,526 (60.8) (16.6) (42.2) 1,283 907 1,967 (47.3) (30.9) (58.6) 
Rapid test used in 
testing event 
                  
   Yes 8,157 1,766 2,011 (16.9) (68.4) (82.2) 4,184 2,657 5,093 (42.7) (35.1) (61.2) 6,826 2,190 2,918 (24.5) (57.2) (75.7) 
   No 2,995 840 1,201 (23.8) (59.5) (78.1) 1,594 1,089 2,353 (46.7) (31.7) (59.4) 2,039 903 2,094 (41.6) (40.5) (69.3) 
  Missing/invalid 6 0 0 (0.0) (100.0) (100.0) 3 0 3 (50.0) (50.0) (100.0) 0 0 6 (100.0) (0.0) (0.0) 
Total 11,158 2,606 3,212 (18.9) (65.7) (81.1) 5,781 3,746 7,449 (43.9) (34.1) (60.7) 8,865 3,093 5,018 (29.6) (52.2) (74.1) 
 
a Interview for partner services was not collected in the 2008-2011 version of the HIV testing form.  Therefore, these data are represented as missing/invalid data. 
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Table 8.  HIV testing and care continuum, including HIV positivity and linkage to care, by demographic characteristics of newly 
identified HIV-positive persons tested in health care and correctional facilities from 59 health department jurisdictions providing 
test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2012. 
Demographic characteristics 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positive 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Age at test (years)                
   <13 3,776 12 (0.3) 4 4 4 (33.3) (33.3) (50.0) 2 1 9 (75.0) (16.7) (66.7) 
   13–19 217,985 386 (0.2) 174 93 119 (30.8) (45.1) (65.2) 137 37 212 (54.9) (35.5) (78.7) 
   20–29 958,133 3,857 (0.4) 1,951 947 959 (24.9) (50.6) (67.3) 1,337 360 2,160 (56.0) (34.7) (78.8) 
   30–39 500,913 2,454 (0.5) 1,295 587 572 (23.3) (52.8) (68.8) 877 192 1,385 (56.4) (35.7) (82.0) 
   40–49 308,914 1,868 (0.6) 973 454 441 (23.6) (52.1) (68.2) 727 131 1,010 (54.1) (38.9) (84.7) 
   50+ 294,983 1,384 (0.5) 740 345 299 (21.6) (53.5) (68.2) 542 93 749 (54.1) (39.2) (85.4) 
   Missing/invalid 12,797 33 (0.3) 17 10 6 (18.2) (51.5) (63.0) 13 2 18 (54.5) (39.4) (86.7) 
Gender                
   Male 986,776 7,586 (0.8) 3,991 1,886 1,709 (22.5) (52.6) (67.9) 2,789 619 4,178 (55.1) (36.8) (81.8) 
   Female 1,285,828 2,209 (0.2) 1,073 512 624 (28.2) (48.6) (67.7) 802 174 1,233 (55.8) (36.3) (82.2) 
   Other 8,659 61 (0.7) 31 22 8 (13.1) (50.8) (58.5) 0 19 42 (68.9) (0.0) (0.0) 
   Declined/not asked 2,032 9 (0.4) 6 1 2 (22.2) (66.7) (85.7) 3 0 6 (66.7) (33.3) (100.0) 
   Missing/invalid 7,753 49 (0.6) 9 8 32 (65.3) (18.4) (52.9) 9 0 40 (81.6) (18.4) (100.0) 
Race/ethnicity                
   White 618,163 1,972 (0.3) 1,006 503 463 (23.5) (51.0) (66.7) 692 135 1,145 (58.1) (35.1) (83.7) 
   Black or African American 1,035,531 5,488 (0.5) 2,591 1,407 1,490 (27.2) (47.2) (64.8) 1,848 523 3,117 (56.8) (33.7) (77.9) 
   Hispanic or Latino 465,098 1,934 (0.4) 1,295 330 309 (16.0) (67.0) (79.7) 952 105 877 (45.3) (49.2) (90.1) 
   Asian 41,150 120 (0.3) 68 29 23 (19.2) (56.7) (70.1) 44 8 68 (56.7) (36.7) (84.6) 
   American Indian or Alaska 
Native 
8,666 47 (0.5) 22 14 11 (23.4) (46.8) (61.1) 16 6 25 (53.2) (34.0) (72.7) 
   Native Hawaiian or Pacific 
Islander 
4,462 18 (0.4) 11 2 5 (27.8) (61.1) (84.6) 8 1 9 (50.0) (44.4) (88.9) 
   Multi-race 12,422 60 (0.5) 38 14 8 (13.3) (63.3) (73.1) 27 7 26 (43.3) (45.0) (79.4) 
   Declined 38,870 96 (0.2) 60 31 5 (5.2) (62.5) (65.9) 12 25 59 (61.5) (12.5) (32.4) 
   Don't know/not asked 70,965 253 (0.4) 63 110 80 (31.6) (24.9) (36.4) 36 6 211 (83.4) (14.2) (85.7) 
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Demographic characteristics 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positive 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
   Missing/invalid 2,174 6 (0.3) 0 0 6 (100.0) (0.0) (0.0) 0 0 6 (100.0) (0.0) (0.0) 
Region                
   Northeast 404,860 1,440 (0.4) 898 307 235 (16.3) (62.4) (74.5) 609 172 659 (45.8) (42.3) (78.0) 
   Midwest 238,772 878 (0.4) 446 164 268 (30.5) (50.8) (73.1) 355 94 429 (48.9) (40.4) (79.1) 
   South 1,398,598 5,972 (0.4) 2,590 1,742 1,640 (27.5) (43.4) (59.8) 1,782 465 3,725 (62.4) (29.8) (79.3) 
   West 228,527 1,289 (0.6) 858 191 240 (18.6) (66.6) (81.8) 528 75 686 (53.2) (41.0) (87.6) 
   U.S. dependent areas 26,744 415 (1.6) 362 36 17 (4.1) (87.2) (91.0) 361 10 44 (10.6) (87.0) (97.3) 
Target population (not required 
for persons who test negative in 
health care settings) 
               
   Men who have sex with men,  
injection drug use 
2,616 101 (3.9) 74 16 11 (10.9) (73.3) (82.2) 58 11 32 (31.7) (57.4) (84.1) 
   Men who have sex with men 91,806 3,556 (3.9) 2,162 711 683 (19.2) (60.8) (75.3) 1,674 340 1,542 (43.4) (47.1) (83.1) 
   Transgender and injection drug 
use 
178 7 (3.9) 2 0 5 (71.4) (28.6) (100.0) 1 0 6 (85.7) (14.3) (100.0) 
   Transgender 6,275 73 (1.2) 42 11 20 (27.4) (57.5) (79.2) 31 4 38 (52.1) (42.5) (88.6) 
   Injection drug use 36,574 147 (0.4) 73 38 36 (24.5) (49.7) (65.8) 52 13 82 (55.8) (35.4) (80.0) 
   Heterosexual males 386,300 1,609 (0.4) 843 359 407 (25.3) (52.4) (70.1) 665 164 780 (48.5) (41.3) (80.2) 
   Heterosexual females 648,818 1,458 (0.2) 809 286 363 (24.9) (55.5) (73.9) 644 134 680 (46.6) (44.2) (82.8) 
  Not asked/no 
risk/missing/invalid 
1,124,934 3,043 (0.3) 1,149 1,019 875 (28.7) (37.8) (53.0) 510 150 2,383 (78.3) (16.8) (77.3) 
Rapid test used in testing 
event 
               
   Yes 1,142,004 6,314 (0.6) 3,557 1,437 1,320 (20.9) (56.3) (71.2) 2,418 623 3,273 (51.8) (38.3) (79.5) 
   No 1,145,931 3,674 (0.3) 1,597 1,003 1,074 (29.2) (43.5) (61.4) 1,217 193 2,264 (61.6) (33.1) (86.3) 
   Missing/invalid 9,566 6 (0.1) 0 0 6 (100.0) (0.0) (0.0) 0 0 6 (100.0) (0.0) (0.0) 
Total 2,297,501 9,994 (0.4) 5,154 2,440 2,400 (24.0) (51.6) (67.9) 3,635 816 5,543 (55.5) (36.4) (81.7) 
      
a Linkage to HIV medical care within 90 days was not collected in the 2008-2011 version of the HIV testing form.  Although this is a required reporting indicator for 2012, data for 18.5% of newly-   
  identified HIV-positive persons identified in health care and correctional facilities in 2012 were reported using the previous version of the testing form.  These data are represented as missing/invalid data. 
55 
 
Table 9.  HIV testing and care continuum, including partner and HIV prevention services, by demographic characteristics of newly 
identified HIV-positive persons tested in health care and correctional facilities from 59 health department jurisdictions providing 
test-level data in the United States, Puerto Rico, and the U.S. Virgin Islands, 2012. 
Demographic 
characteristics 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing/ 
invalid %) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Age at test (years)                   
   <13 5 7 0 (0.0) (41.7) (41.7) 3 7 2 (16.7) (25.0) (30.0) 4 7 1 (8.3) (33.3) (36.4) 
   13–19 282 48 56 (14.5) (73.1) (85.5) 149 65 172 (44.6) (38.6) (69.6) 195 64 127 (32.9) (50.5) (75.3) 
   20–29 2,657 483 717 (18.6) (68.9) (84.6) 1,417 687 1,753 (45.4) (36.7) (67.3) 2,075 689 1,093 (28.3) (53.8) (75.1) 
   30–39 1,592 357 505 (20.6) (64.9) (81.7) 845 506 1,103 (44.9) (34.4) (62.5) 1,303 478 673 (27.4) (53.1) (73.2) 
   40–49 1,170 315 383 (20.5) (62.6) (78.8) 643 428 797 (42.7) (34.4) (60.0) 980 382 506 (27.1) (52.5) (72.0) 
   50+ 853 249 282 (20.4) (61.6) (77.4) 468 339 577 (41.7) (33.8) (58.0) 731 279 374 (27.0) (52.8) (72.4) 
   Missing/invalid 22 5 6 (18.2) (66.7) (81.5) 14 9 10 (30.3) (42.4) (60.9) 16 7 10 (30.3) (48.5) (69.6) 
Gender                   
   Male 5,002 1,099 1,485 (19.6) (65.9) (82.0) 2,708 1,530 3,348 (44.1) (35.7) (63.9) 4,133 1,449 2,004 (26.4) (54.5) (74.0) 
   Female 1,411 345 453 (20.5) (63.9) (80.4) 748 472 989 (44.8) (33.9) (61.3) 1,096 389 724 (32.8) (49.6) (73.8) 
   Other 60 1 0 (0.0) (98.4) (98.4) 52 8 1 (1.6) (85.2) (86.7) 7 45 9 (14.8) (11.5) (13.5) 
Declined/ 
not asked 
5 4 0 (0.0) (55.6) (55.6) 2 4 3 (33.3) (22.2) (33.3) 5 3 1 (11.1) (55.6) (62.5) 
   Missing/invalid 47 2 0 (0.0) (95.9) (95.9) 14 3 32 (65.3) (28.6) (82.4) 12 5 32 (65.3) (24.5) (70.6) 
Race/ethnicity                   
   White 1,312 262 398 (20.2) (66.5) (83.4) 679 390 903 (45.8) (34.4) (63.5) 1,119 390 463 (23.5) (56.7) (74.2) 
   Black or African 
American 
3,559 865 1,064 (19.4) (64.9) (80.4) 1,851 1,144 2,493 (45.4) (33.7) (61.8) 2,795 1,017 1,676 (30.5) (50.9) (73.3) 
   Hispanic or 
Latino 
1,383 192 359 (18.6) (71.5) (87.8) 879 326 729 (37.7) (45.4) (72.9) 1,166 338 430 (22.2) (60.3) (77.5) 
   Asian 80 15 25 (20.8) (66.7) (84.2) 29 32 59 (49.2) (24.2) (47.5) 72 23 25 (20.8) (60.0) (75.8) 
   American Indian 
or Alaska Native 
38 8 1 (2.1) (80.9) (82.6) 18 12 17 (36.2) (38.3) (60.0) 27 13 7 (14.9) (57.4) (67.5) 
   Native Hawaiian 
or Pacific Islander 
13 2 3 (16.7) (72.2) (86.7) 8 2 8 (44.4) (44.4) (80.0) 10 3 5 (27.8) (55.6) (76.9) 
   Multi-race 53 4 3 (5.0) (88.3) (93.0) 31 10 19 (31.7) (51.7) (75.6) 38 15 7 (11.7) (63.3) (71.7) 
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Demographic 
characteristics 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing/ 
invalid %) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
   Declined 61 16 19 (19.8) (63.5) (79.2) 12 19 65 (67.7) (12.5) (38.7) 9 6 81 (84.4) (9.4) (60.0) 
   Don't know/not 
asked 
76 100 77 (30.4) (30.0) (43.2) 32 106 115 (45.5) (12.6) (23.2) 67 101 85 (33.6) (26.5) (39.9) 
   Missing/invalid 6 0 0 (0.0) (100.0) (100.0) 0 0 6 (100.0) (0.0) (0.0) 1 0 5 (83.3) (16.7) (100.0) 
Region                   
   Northeast 872 374 194 (13.5) (60.6) (70.0) 268 454 718 (49.9) (18.6) (37.1) 799 341 300 (20.8) (55.5) (70.1) 
   Midwest 708 66 104 (11.8) (80.6) (91.5) 408 88 382 (43.5) (46.5) (82.3) 630 89 159 (18.1) (71.8) (87.6) 
   South 3,624 924 1,424 (23.8) (60.7) (79.7) 2,069 1,208 2,695 (45.1) (34.6) (63.1) 2,690 1,115 2,167 (36.3) (45.0) (70.7) 
   West 980 83 226 (17.5) (76.0) (92.2) 412 264 613 (47.6) (32.0) (60.9) 858 274 157 (12.2) (66.6) (75.8) 
   U.S. dependent 
areas 
397 17 1 (0.2) (95.7) (95.9) 382 27 6 (1.4) (92.0) (93.4) 327 87 1 (0.2) (78.8) (79.0) 
Target population 
(not required for 
persons who test 
negative in health 
care settings) 
                  
   Men who have 
sex with men,  
injection drug use 
78 11 12 (11.9) (77.2) (87.6) 45 23 33 (32.7) (44.6) (66.2) 59 28 14 (13.9) (58.4) (67.8) 
   Men who have 
sex with men 
2,869 402 285 (8.0) (80.7) (87.7) 1,679 643 1,234 (34.7) (47.2) (72.3) 2,348 610 598 (16.8) (66.0) (79.4) 
   Transgender and 
injection drug use 
6 0 1 (14.3) (85.7) (100.0) 0 1 6 (85.7) (0.0) (0.0) 4 0 3 (42.9) (57.1) (100.0) 
   Transgender 50 13 10 (13.7) (68.5) (79.4) 15 23 35 (47.9) (20.5) (39.5) 47 15 11 (15.1) (64.4) (75.8) 
   Injection drug use 89 26 32 (21.8) (60.5) (77.4) 45 36 66 (44.9) (30.6) (55.6) 81 21 45 (30.6) (55.1) (79.4) 
   Heterosexual 
males 
1,147 196 266 (16.5) (71.3) (85.4) 630 304 675 (42.0) (39.2) (67.5) 902 264 443 (27.5) (56.1) (77.4) 
   Heterosexual 
females 
1,082 191 185 (12.7) (74.2) (85.0) 602 282 574 (39.4) (41.3) (68.1) 843 230 385 (26.4) (57.8) (78.6) 
   Not asked/no 
risk/missing/ 
invalid 
1,260 625 1,158 (38.1) (41.4) (66.8) 523 729 1,791 (58.9) (16.9) (41.8) 1020 738 1,285 (42.2) (33.5) (58.0) 
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Demographic 
characteristics 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing/ 
invalid %) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Rapid test used in 
testing event 
                  
   Yes 4,420 877 1,017 (16.1) (70.0) (83.4) 2,364 1,287 2,663 (42.2) (37.4) (64.7) 3,699 1,197 1,418 (22.5) (58.6) (75.6) 
   No 2,155 587 932 (25.4) (58.7) (78.6) 1,172 754 1,748 (47.6) (31.9) (60.9) 1,605 709 1,360 (37.0) (43.7) (69.4) 
   Missing/invalid 6 0 0 (0.0) (100.0) (100.0) 3 0 3 (50.0) (50.0) (100.0) 0 0 6 (100.0) (0.0) (0.0) 
Total 6,581 1,464 1,949 (19.5) (65.8) (81.8) 3,539 2,041 4,414 (44.2) (35.4) (63.4) 5,304 1,906 2,784 (27.9) (53.1) (73.6) 
 
a Interview for partner services was not collected in the 2008-2011 version of the HIV testing form.  Therefore, these data are represented as missing/invalid data. 
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Table 10.  HIV testing and care continuum, including HIV positivity and linkage to care, by demographic characteristics of newly 
identified HIV-positive persons tested in non-health care facilities from 59 health department jurisdictions providing test-level data 
in the United States, Puerto Rico, and the U.S. Virgin Islands, 2012. 
Demographic characteristics 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positive 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Age at test (years)                
   <13 1,355 6 (0.4) 2 1 3 (50.0) (33.3) (66.7) 2 0 4 (66.7) (33.3) (100.0) 
   13–19 85,347 220 (0.3) 114 51 55 (25.0) (51.8) (69.1) 77 19 124 (56.4) (35.0) (80.2) 
   20–29 386,744 2,852 (0.7) 1,455 694 703 (24.6) (51.0) (67.7) 997 196 1,659 (58.2) (35.0) (83.6) 
   30–39 223,743 1,627 (0.7) 891 399 337 (20.7) (54.8) (69.1) 598 87 942 (57.9) (36.8) (87.3) 
   40–49 153,769 1,341 (0.9) 666 362 313 (23.3) (49.7) (64.8) 488 105 748 (55.8) (36.4) (82.3) 
   50+ 127,960 912 (0.7) 412 306 194 (21.3) (45.2) (57.4) 315 98 499 (54.7) (34.5) (76.3) 
   Missing/invalid 6,693 18 (0.3) 7 4 7 (38.9) (38.9) (63.6) 4 1 13 (72.2) (22.2) (80.0) 
Gender                
   Male 585,297 5,744 (1.0) 2,962 1,467 1,315 (22.9) (51.6) (66.9) 2,075 405 3,264 (56.8) (36.1) (83.7) 
   Female 391,825 1,092 (0.3) 518 312 262 (24.0) (47.4) (62.4) 356 91 645 (59.1) (32.6) (79.6) 
   Other 81 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
   Declined/not asked 799 4 (0.5) 1 3 0 (0.0) (25.0) (25.0) 1 1 2 (50.0) (25.0) (50.0) 
   Missing/invalid 2,312 10 (0.4) 7 1 2 (20.0) (70.0) (87.5) 6 0 4 (40.0) (60.0) (100.0) 
Race/ethnicity                
   White 276,908 1,551 (0.6) 845 404 302 (19.5) (54.5) (67.7) 600 83 868 (56.0) (38.7) (87.8) 
   Black or African American 408,307 3,392 (0.8) 1,547 939 906 (26.7) (45.6) (62.2) 1,121 277 1,994 (58.8) (33.0) (80.2) 
   Hispanic or Latino 221,224 1,561 (0.7) 923 347 291 (18.6) (59.1) (72.7) 624 99 838 (53.7) (40.0) (86.3) 
   Asian 21,660 116 (0.5) 65 31 20 (17.2) (56.0) (67.7) 51 13 52 (44.8) (44.0) (79.7) 
   American Indian or Alaska 
Native 
7,888 40 (0.5) 11 17 12 (30.0) (27.5) (39.3) 6 3 31 (77.5) (15.0) (66.7) 
   Native Hawaiian or Pacific 
Islander 
3,684 23 (0.6) 13 6 4 (17.4) (56.5) (68.4) 9 1 13 (56.5) (39.1) (90.0) 
   Multi-race 9,974 89 (0.9) 50 24 15 (16.9) (56.2) (67.6) 35 5 49 (55.1) (39.3) (87.5) 
   Declined 13,580 91 (0.7) 53 28 10 (11.0) (58.2) (65.4) 8 21 62 (68.1) (8.8) (27.6) 
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Demographic characteristics 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positive 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
   Don't know/not asked 15,543 81 (0.5) 40 21 20 (24.7) (49.4) (65.6) 27 4 50 (61.7) (33.3) (87.1) 
   Missing/invalid 6,843 32 (0.5) 0 0 32 (100.0) (0.0) (0.0) 0 0 32 (100.0) (0.0) (0.0) 
Region                
   Northeast 230,191 1,070 (0.5) 637 222 211 (19.7) (59.5) (74.2) 494 98 478 (44.7) (46.2) (83.4) 
   Midwest 71,537 606 (0.8) 284 118 204 (33.7) (46.9) (70.6) 254 65 287 (47.4) (41.9) (79.6) 
   South 536,004 4,048 (0.8) 1,872 1,163 1,013 (25.0) (46.2) (61.7) 1,219 287 2,542 (62.8) (30.1) (80.9) 
   West 137,615 1,182 (0.9) 718 286 178 (15.1) (60.7) (71.5) 481 48 653 (55.2) (40.7) (90.9) 
   U.S. dependent areas 10,264 70 (0.7) 36 28 6 (8.6) (51.4) (56.3) 33 8 29 (41.4) (47.1) (80.5) 
Target population (not required 
for persons who test negative in 
health care settings) 
               
   Men who have sex with men 
and injection drug use 
3,758 135 (3.6) 67 37 31 (23.0) (49.6) (64.4) 47 12 76 (56.3) (34.8) (79.7) 
   Men who have sex with men 142,935 3,688 (2.6) 2,047 876 765 (20.7) (55.5) (70.0) 1,550 232 1,906 (51.7) (42.0) (87.0) 
   Transgender and injection drug 
use 
337 9 (2.7) 5 2 2 (22.2) (55.6) (71.4) 3 1 5 (55.6) (33.3) (75.0) 
   Transgender 4,960 117 (2.4) 54 32 31 (26.5) (46.2) (62.8) 40 8 69 (59.0) (34.2) (83.3) 
   Injection drug use 39,761 225 (0.6) 72 91 62 (27.6) (32.0) (44.2) 59 34 132 (58.7) (26.2) (63.4) 
   Heterosexual males 223,204 948 (0.4) 424 286 238 (25.1) (44.7) (59.7) 310 112 526 (55.5) (32.7) (73.5) 
   Heterosexual females 228,295 741 (0.3) 363 208 170 (22.9) (49.0) (63.6) 260 69 412 (55.6) (35.1) (79.0) 
   Not asked/no risk/missing/invalid 342,361 1,113 (0.3) 515 285 313 (28.1) (46.3) (64.4) 212 38 863 (77.5) (19.0) (84.8) 
Rapid test used in testing event                
   Yes 713,197 5,617 (0.8) 3,056 1,401 1,160 (20.7) (54.4) (68.6) 2,164 400 3,053 (54.4) (38.5) (84.4) 
   No 272,313 1,359 (0.5) 491 416 452 (33.3) (36.1) (54.1) 317 106 936 (68.9) (23.3) (74.9) 
   Missing/invalid 101 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
Total 985,611 6,976 (0.7) 3,547 1,817 1,612 (23.1) (50.8) (66.1) 2,481 506 3,989 (57.2) (35.6) (83.1) 
     
 a Linkage to HIV medical care within 90 days was not collected in the 2008-2011 version of the HIV testing form.  Although this is a required reporting indicator for 2012, data for 11.4% of newly identified     
   HIV-positive persons identified in non-health care facilities in 2012 were reported using the previous version of the testing form.  Therefore, these data are represented as missing/invalid data. 
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Table 11.  HIV testing and care continuum, including partner and HIV prevention services, by demographic characteristics of newly 
identified HIV-positive persons tested in non-health care facilities from 59 health department jurisdictions providing test-level data 
in the United States, Puerto Rico, and the U.S. Virgin Islands, 2012. 
Demographic 
characteristics 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Age at test (years)                   
   <13 4 1 1 (16.7) (66.7) (80.0) 1 1 4 (66.7) (16.7) (50.0) 3 0 3 (50.0) (50.0) (100.0) 
   13–19 140 34 46 (20.9) (63.6) (80.5) 76 53 91 (41.4) (34.5) (58.9) 119 27 74 (33.6) (54.1) (81.5) 
   20–29 1,937 398 517 (18.1) (67.9) (83.0) 946 589 1,317 (46.2) (33.2) (61.6) 1,498 461 893 (31.3) (52.5) (76.5) 
   30–39 1,072 258 297 (18.3) (65.9) (80.6) 521 384 722 (44.4) (32.0) (57.6) 844 298 485 (29.8) (51.9) (73.9) 
   40–49 873 232 236 (17.6) (65.1) (79.0) 403 361 577 (43.0) (30.1) (52.7) 677 212 452 (33.7) (50.5) (76.2) 
   50+ 536 213 163 (17.9) (58.8) (71.6) 285 310 317 (34.8) (31.3) (47.9) 413 180 319 (35.0) (45.3) (69.6) 
   Missing/invalid 12 3 3 (16.7) (66.7) (80.0) 10 4 4 (22.2) (55.6) (71.4) 7 6 5 (27.8) (38.9) (53.8) 
Gender                   
   Male 3,845 886 1,013 (17.6) (66.9) (81.3) 1,850 1,340 2,554 (44.5) (32.2) (58.0) 3,005 961 1,778 (31.0) (52.3) (75.8) 
   Female 636 228 228 (20.9) (58.2) (73.6) 354 331 407 (37.3) (32.4) (51.7) 475 194 423 (38.7) (43.5) (71.0) 
   Declined/not asked 2 2 0 (0.0) (50.0) (50.0) 1 3 0 (0.0) (25.0) (25.0) 3 1 0 (0.0) (75.0) (75.0) 
   Missing/invalid 10 0 0 (0.0) (100.0) (100.0) 8 0 2 (20.0) (80.0) (100.0) 8 1 1 (10.0) (80.0) (88.9) 
Race/ethnicity                   
   White 1,064 239 248 (16.0) (68.6) (81.7) 555 372 624 (40.2) (35.8) (59.9) 901 307 343 (22.1) (58.1) (74.6) 
   Black or African 
American 
2,197 602 593 (17.5) (64.8) (78.5) 1,091 846 1,455 (42.9) (32.2) (56.3) 1,615 557 1,220 (36.0) (47.6) (74.4) 
   Hispanic or Latino 1,012 197 352 (22.5) (64.8) (83.7) 503 350 708 (45.4) (32.2) (59.0) 842 243 476 (30.5) (53.9) (77.6) 
   Asian 80 16 20 (17.2) (69.0) (83.3) 21 29 66 (56.9) (18.1) (42.0) 67 20 29 (25.0) (57.8) (77.0) 
American Indian or 
Alaska Native 
25 9 6 (15.0) (62.5) (73.5) 10 11 19 (47.5) (25.0) (47.6) 21 8 11 (27.5) (52.5) (72.4) 
   Native Hawaiian or 
Pacific Islander 
15 2 6 (26.1) (65.2) (88.2) 6 3 14 (60.9) (26.1) (66.7) 13 4 6 (26.1) (56.5) (76.5) 
   Multi-race 65 13 11 (12.4) (73.0) (83.3) 35 19 35 (39.3) (39.3) (64.8) 48 20 21 (23.6) (53.9) (70.6) 
   Declined 48 38 5 (5.5) (52.7) (55.8) 3 42 46 (50.5) (3.3) (6.7) 25 4 62 (68.1) (27.5) (86.2) 
   Don't know/not asked 36 23 22 (27.2) (44.4) (61.0) 18 30 33 (40.7) (22.2) (37.5) 29 21 31 (38.3) (35.8) (58.0) 
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Demographic 
characteristics 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
   Missing/invalid 32 0 0 (0.0) (100.0) (100.0) 0 0 32 (100.0) (0.0) (0.0) 0 0 32 (100.0) (0.0) (0.0) 
Region                   
   Northeast 540 331 199 (18.6) (50.5) (62.0) 172 396 502 (46.9) (16.1) (30.3) 544 258 268 (25.0) (50.8) (67.8) 
   Midwest 445 77 84 (13.9) (73.4) (85.2) 255 110 241 (39.8) (42.1) (69.9) 403 105 98 (16.2) (66.5) (79.3) 
   South 2,633 588 827 (20.4) (65.0) (81.7) 1,536 930 1,582 (39.1) (37.9) (62.3) 1,826 621 1,601 (39.6) (45.1) (74.6) 
   West 921 111 150 (12.7) (77.9) (89.2) 250 233 699 (59.1) (21.2) (51.8) 740 181 261 (22.1) (62.6) (80.3) 
   U.S. dependent areas 35 32 3 (4.3) (50.0) (52.2) 29 33 8 (11.4) (41.4) (46.8) 48 19 3 (4.3) (68.6) (71.6) 
Target population (not 
required for persons who 
test negative in health 
care settings) 
                  
   Men who have sex 
with men and injection 
drug use 
89 21 25 (18.5) (65.9) (80.9) 40 38 57 (42.2) (29.6) (51.3) 77 23 35 (25.9) (57.0) (77.0) 
   Men who have sex 
with men 
2,775 510 403 (10.9) (75.2) (84.5) 1,360 820 1,508 (40.9) (36.9) (62.4) 2,257 631 800 (21.7) (61.2) (78.2) 
   Transgender and 
injection drug use 
6 1 2 (22.2) (66.7) (85.7) 1 2 6 (66.7) (11.1) (33.3) 6 2 1 (11.1) (66.7) (75.0) 
   Transgender 75 22 20 (17.1) (64.1) (77.3) 28 26 63 (53.8) (23.9) (51.9) 64 25 28 (23.9) (54.7) (71.9) 
   Injection drug use 102 66 57 (25.3) (45.3) (60.7) 51 101 73 (32.4) (22.7) (33.6) 103 39 83 (36.9) (45.8) (72.5) 
   Heterosexual males 639 203 106 (11.2) (67.4) (75.9) 327 276 345 (36.4) (34.5) (54.2) 433 156 359 (37.9) (45.7) (73.5) 
   Heterosexual females 491 149 101 (13.6) (66.3) (76.7) 270 225 246 (33.2) (36.4) (54.5) 358 139 244 (32.9) (48.3) (72.0) 
   Not asked/no 
risk/missing/invalid 
397 167 549 (49.3) (35.7) (70.4) 165 214 734 (65.9) (14.8) (43.5) 263 169 679 (61.0) (23.6) (60.6) 
Rapid test used in 
testing event 
                  
   Yes 3,736 887 994 (17.7) (66.5) (80.8) 1,820 1,368 2,429 (43.2) (32.4) (57.1) 3,127 991 1,499 (26.7) (55.7) (75.9) 
   No 838 252 269 (19.8) (61.7) (76.9) 422 334 603 (44.4) (31.1) (55.8) 434 193 732 (53.9) (31.9) (69.2) 
Total 4,574 1,139 1,263 (18.1) (65.6) (80.1) 2,242 1,702 3,032 (43.5) (32.1) (56.8) 3,561 1,184 2,231 (32.0) (51.0) (75.0) 
 
aInterview for partner services was not collected in the 2008-2011 version of the HIV testing form.  Therefore, these data are represented as missing/invalid data. 
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Table 12.  HIV testing and care continuum, including HIV positivity and linkage to care, by demographic characteristics of newly 
identified HIV-positive men who have sex with men (MSM) from 59 health department jurisdictions providing test-level data in the 
United States, Puerto Rico, and the U.S. Virgin Islands, 2012. 
Demographic 
characteristics 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positive 
tests 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Age at test (years)                
   <13 199 6 (3.0) 3 1 2 (33.3) (50.0) (75.0) 3 1 2 (33.3) (50.0) (75.0) 
   13–19 13,704 300 (2.2) 177 61 62 (20.7) (59.0) (74.4) 142 28 130 (43.3) (47.3) (83.5) 
   20–29 106,668 3,885 (3.6) 2,195 870 820 (21.1) (56.5) (71.6) 1,635 347 1,903 (49.0) (42.1) (82.5) 
   30–39 55,015 1,783 (3.2) 1,095 377 311 (17.4) (61.4) (74.4) 829 120 834 (46.8) (46.5) (87.4) 
   40–49 36,876 1,028 (2.8) 604 222 202 (19.6) (58.8) (73.1) 507 61 460 (44.7) (49.3) (89.3) 
   50+ 27,361 469 (1.7) 273 106 90 (19.2) (58.2) (72.0) 212 37 220 (46.9) (45.2) (85.1) 
   Missing/invalid 1,340 10 (0.7) 4 3 3 (30.0) (40.0) (57.1) 2 1 7 (70.0) (20.0) (66.7) 
Race/ethnicity                
   White 108,246 1,986 (1.8) 1,185 423 378 (19.0) (59.7) (73.7) 934 120 932 (46.9) (47.0) (88.6) 
   Black or African American 55,979 3,206 (5.7) 1,681 755 770 (24.0) (52.4) (69.0) 1,286 306 1,614 (50.3) (40.1) (80.8) 
   Hispanic or Latino 54,110 1,817 (3.4) 1,219 347 251 (13.8) (67.1) (77.8) 932 112 773 (42.5) (51.3) (89.3) 
   Asian 9,763 145 (1.5) 85 31 29 (20.0) (58.6) (73.3) 66 14 65 (44.8) (45.5) (82.5) 
   American Indian or Alaska 
Native 
1,340 48 (3.6) 22 16 10 (20.8) (45.8) (57.9) 14 7 27 (56.3) (29.2) (66.7) 
   Native Hawaiian or Pacific 
Islander 
1,247 29 (2.3) 17 7 5 (17.2) (58.6) (70.8) 13 2 14 (48.3) (44.8) (86.7) 
   Multi-race 3,976 92 (2.3) 59 18 15 (16.3) (64.1) (76.6) 47 7 38 (41.3) (51.1) (87.0) 
   Declined 3,176 86 (2.7) 48 33 5 (5.8) (55.8) (59.3) 13 25 48 (55.8) (15.1) (34.2) 
   Don't know/not asked 3,091 57 (1.8) 35 10 12 (21.1) (61.4) (77.8) 25 2 30 (52.6) (43.9) (92.6) 
   Missing/invalid 235 15 (6.4) 0 0 15 (100.0) (0.0) (0.0) 0 0 15 (100.0) (0.0) (0.0) 
Region                
   Northeast 37,158 1,087 (2.9) 777 170 140 (12.9) (71.5) (82.0) 586 102 399 (36.7) (53.9) (85.2) 
   Midwest 36,005 932 (2.6) 487 174 271 (29.1) (52.3) (73.7) 401 104 427 (45.8) (43.0) (79.4) 
   South 93,650 3,777 (4.0) 1,931 946 900 (23.8) (51.1) (67.1) 1,465 300 2,012 (53.3) (38.8) (83.0) 
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Demographic 
characteristics 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positive 
tests 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
   West 70,632 1,459 (2.1) 969 317 173 (11.9) (66.4) (75.3) 694 83 682 (46.7) (47.6) (89.3) 
   U.S. dependent areas 3,718 226 (6.1) 187 33 6 (2.7) (82.7) (85.0) 184 6 36 (15.9) (81.4) (96.8) 
Testing site type                
   Health care facilities 
includes correctional facility 
clinics 
94,422 3,657 (3.9) 2,236 727 694 (19.0) (61.1) (75.5) 1,732 351 1,574 (43.0) (47.4) (83.1) 
   Non-health care facilities 146,693 3,823 (2.6) 2,114 913 796 (20.8) (55.3) (69.8) 1,597 244 1,982 (51.8) (41.8) (86.7) 
   Missing/invalid 48 1 (2.1) 1 0 0 (0.0) (100.0) (100.0) 1 0 0 (0.0) (100.0) (100.0) 
Rapid test used in testing 
event 
               
   Yes 203,517 5,893 (2.9) 3,520 1,330 1,043 (17.7) (59.7) (72.6) 2,637 492 2,764 (46.9) (44.7) (84.3) 
   No 37,624 1,587 (4.2) 831 310 446 (28.1) (52.4) (72.8) 693 103 791 (49.8) (43.7) (87.1) 
   Missing/invalid 22 1 (4.5) 0 0 1 (100.0) (0.0) (0.0) 0 0 1 (100.0) (0.0) (0.0) 
Total 241,163 7,481 (3.1) 4,351 1,640 1,490 (19.9) (58.2) (72.6) 3,330 595 3,556 (47.5) (44.5) (84.8) 
      
 a Linkage to HIV medical care within 90 days was not collected in the 2008-2011 version of the HIV testing form.  Although this is a required reporting indicator for 2012, data for 12.3% of newly identified     
    HIV-positive MSM in 2012 were reported using the previous version of the testing form.  Therefore, these data are represented as missing/invalid data. 
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Table 13.  HIV testing and care continuum, including partner and HIV prevention services, by demographic characteristics of newly 
identified HIV-positive MSM from 59 health department jurisdictions providing test-level data in the United States, Puerto Rico, and 
the U.S. Virgin Islands, 2012. 
Demographic 
characteristics 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Age at test (years)                   
   <13 3 2 1 (16.7) (50.0) (60.0) 2 2 2 (33.3) (33.3) (50.0) 2 2 2 (33.3) (33.3) (50.0) 
   13–19 244 37 19 (6.3) (81.3) (86.8) 149 52 99 (33.0) (49.7) (74.1) 196 50 54 (18.0) (65.3) (79.7) 
   20–29 3,031 487 367 (9.4) (78.0) (86.2) 1,653 742 1,490 (38.4) (42.5) (69.0) 2,447 631 807 (20.8) (63.0) (79.5) 
   30–39 1,368 244 171 (9.6) (76.7) (84.9) 730 397 656 (36.8) (40.9) (64.8) 1,135 346 302 (16.9) (63.7) (76.6) 
   40–49 807 107 114 (11.1) (78.5) (88.3) 401 213 414 (40.3) (39.0) (65.3) 650 172 206 (20.0) (63.2) (79.1) 
   50+ 351 66 52 (11.1) (74.8) (84.2) 184 117 168 (35.8) (39.2) (61.1) 305 90 74 (15.8) (65.0) (77.2) 
   Missing/invalid 7 2 1 (10.0) (70.0) (77.8) 5 2 3 (30.0) (50.0) (71.4) 6 2 2 (20.0) (60.0) (75.0) 
Race/ethnicity                   
   White 1,587 219 180 (9.1) (79.9) (87.9) 875 398 713 (35.9) (44.1) (68.7) 1,346 364 276 (13.9) (67.8) (78.7) 
   Black or African 
American 
2,441 444 321 (10.0) (76.1) (84.6) 1,276 628 1,302 (40.6) (39.8) (67.0) 1,951 519 736 (23.0) (60.9) (79.0) 
   Hispanic or Latino 1,436 207 174 (9.6) (79.0) (87.4) 833 380 604 (33.2) (45.8) (68.7) 1,188 338 291 (16.0) (65.4) (77.9) 
   Asian 110 20 15 (10.3) (75.9) (84.6) 35 42 68 (46.9) (24.1) (45.5) 95 26 24 (16.6) (65.5) (78.5) 
   American Indian or 
Alaska Native 
38 7 3 (6.3) (79.2) (84.4) 20 10 18 (37.5) (41.7) (66.7) 28 11 9 (18.8) (58.3) (71.8) 
   Native Hawaiian or 
Pacific Islander 
23 2 4 (13.8) (79.3) (92.0) 11 3 15 (51.7) (37.9) (78.6) 21 5 3 (10.3) (72.4) (80.8) 
   Multi-race 78 8 6 (6.5) (84.8) (90.7) 51 16 25 (27.2) (55.4) (76.1) 55 20 17 (18.5) (59.8) (73.3) 
   Declined 51 24 11 (12.8) (59.3) (68.0) 8 29 49 (57.0) (9.3) (21.6) 23 2 61 (70.9) (26.7) (92.0) 
   Don't know/not asked 32 14 11 (19.3) (56.1) (69.6) 15 19 23 (40.4) (26.3) (44.1) 33 8 16 (28.1) (57.9) (80.5) 
   Missing/invalid 15 0 0 (0.0) (100.0) (100.0) 0 0 15 (100.0) (0.0) (0.0) 1 0 14 (93.3) (6.7) (100.0) 
Region                   
   Northeast 721 275 91 (8.4) (66.3) (72.4) 207 341 539 (49.6) (19.0) (37.8) 682 219 186 (17.1) (62.7) (75.7) 
   Midwest 771 77 84 (9.0) (82.7) (90.9) 464 114 354 (38.0) (49.8) (80.3) 703 108 121 (13.0) (75.4) (86.7) 
   South 2,947 429 401 (10.6) (78.0) (87.3) 1,806 721 1,250 (33.1) (47.8) (71.5) 2,228 622 927 (24.5) (59.0) (78.2) 
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Demographic 
characteristics 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
   West 1,180 131 148 (10.1) (80.9) (90.0) 460 314 685 (46.9) (31.5) (59.4) 954 293 212 (14.5) (65.4) (76.5) 
   U.S. dependent areas 192 33 1 (0.4) (85.0) (85.3) 187 35 4 (1.8) (82.7) (84.2) 174 51 1 (0.4) (77.0) (77.3) 
Testing site type                   
   Health care facilities 
includes correctional 
facility clinics 
2,947 413 297 (8.1) (80.6) (87.7) 1,724 666 1,267 (34.6) (47.1) (72.1) 2,407 638 612 (16.7) (65.8) (79.0) 
   Non-health care 
facilities 
2,864 531 428 (11.2) (74.9) (84.4) 1,400 858 1,565 (40.9) (36.6) (62.0) 2,334 654 835 (21.8) (61.1) (78.1) 
   Missing/invalid 0 1 0 (0.0) (0.0) (0.0) 0 1 0 (0.0) (0.0) (0.0) 0 1 0 (0.0) (0.0) (0.0) 
Rapid test used in 
testing event 
                  
   Yes 4,546 785 562 (9.5) (77.1) (85.3) 2,387 1,259 2,247 (38.1) (40.5) (65.5) 3,851 1,045 997 (16.9) (65.3) (78.7) 
   No 1,264 160 163 (10.3) (79.6) (88.8) 737 266 584 (36.8) (46.4) (73.5) 890 248 449 (28.3) (56.1) (78.2) 
   Missing/invalid 1 0 0 (0.0) (100.0) (100.0) 0 0 1 (100.0) (0.0) (0.0) 0 0 1 (100.0) (0.0) (0.0) 
Total 5,811 945 725 (9.7) (77.7) (86.0) 3,124 1,525 2,832 (37.9) (41.8) (67.2) 4,741 1,293 1,447 (19.3) (63.4) (78.6) 
 
a Interview for partner services was not collected in the 2008-2011 version of the HIV testing form.  Therefore, these data are represented as missing/invalid data. 
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Table 14.  HIV testing and care continuum, including HIV positivity and linkage to care, by demographic characteristics of newly 
identified HIV-positive heterosexual females from 59 health department jurisdictions providing test-level data in the United States, 
Puerto Rico, and the U.S. Virgin Islands, 2012. 
Demographic 
characteristics 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positive 
tests 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked Not linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Age at test (years)                
   <13 642 3 (0.5) 1 1 1 (33.3) (33.3) (50.0) 0 0 3 (100.0) (0.0) (0.0) 
   13–19 109,158 93 (0.1) 41 21 31 (33.3) (44.1) (66.1) 34 7 52 (55.9) (36.6) (82.9) 
   20–29 414,545 586 (0.1) 294 126 166 (28.3) (50.2) (70.0) 218 48 320 (54.6) (37.2) (82.0) 
   30–39 194,886 545 (0.3) 291 120 134 (24.6) (53.4) (70.8) 221 45 279 (51.2) (40.6) (83.1) 
   40–49 98,204 583 (0.6) 312 138 133 (22.8) (53.5) (69.3) 239 64 280 (48.0) (41.0) (78.9) 
   50+ 56,103 379 (0.7) 226 87 66 (17.4) (59.6) (72.2) 185 38 156 (41.2) (48.8) (83.0) 
   Missing/invalid 3,899 13 (0.3) 7 2 4 (30.8) (53.8) (77.8) 7 1 5 (38.5) (53.8) (87.5) 
Race/ethnicity                
   White 246,638 265 (0.1) 120 69 76 (28.7) (45.3) (63.5) 97 25 143 (54.0) (36.6) (79.5) 
   Black or African 
American 
408,328 1,508 (0.4) 771 340 397 (26.3) (51.1) (69.4) 580 139 789 (52.3) (38.5) (80.7) 
   Hispanic or Latino 170,646 331 (0.2) 229 59 43 (13.0) (69.2) (79.5) 202 25 104 (31.4) (61.0) (89.0) 
   Asian 11,476 10 (0.1) 7 3 0 (0.0) (70.0) (70.0) 6 0 4 (40.0) (60.0) (100.0) 
   American Indian or 
Alaska Native 
5,140 5 (0.1) 1 3 1 (20.0) (20.0) (25.0) 1 1 3 (60.0) (20.0) (50.0) 
Native Hawaiian or 
Pacific Islander 
1,650 1 (0.1) 1 0 0 (0.0) (100.0) (100.0) 1 0 0 (0.0) (100.0) (100.0) 
   Multi-race 7,333 15 (0.2) 8 6 1 (6.7) (53.3) (57.1) 7 4 4 (26.7) (46.7) (63.6) 
   Declined 14,180 30 (0.2) 22 7 1 (3.3) (73.3) (75.9) 2 7 21 (70.0) (6.7) (22.2) 
   Don't know/not asked 8,096 29 (0.4) 13 8 8 (27.6) (44.8) (61.9) 8 2 19 (65.5) (27.6) (80.0) 
   Missing/invalid 3,950 8 (0.2) 0 0 8 (100.0) (0.0) (0.0) 0 0 8 (100.0) (0.0) (0.0) 
Region                
   Northeast 105,214 366 (0.3) 222 94 50 (13.7) (60.7) (70.3) 174 50 142 (38.8) (47.5) (77.7) 
   Midwest 70,571 145 (0.2) 67 28 50 (34.5) (46.2) (70.5) 55 16 74 (51.0) (37.9) (77.5) 
   South 636,619 1,462 (0.2) 712 343 407 (27.8) (48.7) (67.5) 530 128 804 (55.0) (36.3) (80.5) 
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Demographic 
characteristics 
HIV testing events Linkage to HIV medical care within any timeframe Linkage to HIV medical care in 90 daysa 
All testing 
events 
New 
positive 
tests 
(New 
positive 
%) Linked 
Not 
linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Linked Not linked 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
   West 51,218 121 (0.2) 79 22 20 (16.5) (65.3) (78.2) 53 6 62 (51.2) (43.8) (89.8) 
   U.S. dependent areas 13,815 108 (0.8) 92 8 8 (7.4) (85.2) (92.0) 92 3 13 (12.0) (85.2) (96.8) 
Testing site type                
   Health care facilities 
including correctional 
facility clinics 
648,818 1,458 (0.2) 809 286 363 (24.9) (55.5) (73.9) 644 134 680 (46.6) (44.2) (82.8) 
   Non-health care facilities 228,295 741 (0.3) 363 208 170 (22.9) (49.0) (63.6) 260 69 412 (55.6) (35.1) (79.0) 
   Other facilities 1 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
   Missing/invalid 323 3 (0.9) 0 1 2 (66.7) (0.0) (0.0) 0 0 3 (100.0) (0.0) (0.0) 
Rapid test used in testing 
event 
               
   Yes 416,818 1,488 (0.4) 817 361 310 (20.8) (54.9) (69.4) 600 153 735 (49.4) (40.3) (79.7) 
   No 460,401 714 (0.2) 355 134 225 (31.5) (49.7) (72.6) 304 50 360 (50.4) (42.6) (85.9) 
   Missing/invalid 218 0 (0.0) 0 0 0 (0.0) (0.0) (0.0) 0 0 0 (0.0) (0.0) (0.0) 
Total 877,437 2,202 (0.3) 1,172 495 535 (24.3) (53.2) (70.3) 904 203 1,095 (49.7) (41.1) (81.7) 
         
a Linkage to HIV medical care within 90 days was not collected in the 2008-2011 version of the HIV testing form.  Although this is a required reporting indicator for 2012, data for 19.7% of newly identified     
     HIV-positive heterosexual females in 2012 were reported using the previous version of the testing form.  Therefore, these data are represented as missing/invalid data. 
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Table 15.  HIV testing and care continuum, including partner and HIV prevention services, by demographic characteristics of newly 
identified HIV-positive heterosexual females from 59 health department jurisdictions providing test-level data in the United States, 
Puerto Rico, and the U.S. Virgin Islands, 2012. 
Demographic 
characteristics 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator %) 
Age at test (years)                   
   <13 1 2 0 (0.0) (33.3) (33.3) 1 2 0 (0.0) (33.3) (33.3) 1 2 0 (0.0) (33.3) (33.3) 
   13–19 67 11 15 (16.1) (72.0) (85.9) 32 21 40 (43.0) (34.4) (60.4) 51 8 34 (36.6) (54.8) (86.4) 
   20–29 438 67 81 (13.8) (74.7) (86.7) 222 116 248 (42.3) (37.9) (65.7) 301 97 188 (32.1) (51.4) (75.6) 
   30–39 395 72 78 (14.3) (72.5) (84.6) 220 112 213 (39.1) (40.4) (66.3) 297 92 156 (28.6) (54.5) (76.3) 
   40–49 396 115 72 (12.3) (67.9) (77.5) 229 153 201 (34.5) (39.3) (59.9) 320 99 164 (28.1) (54.9) (76.4) 
   50+ 267 73 39 (10.3) (70.4) (78.5) 162 101 116 (30.6) (42.7) (61.6) 222 72 85 (22.4) (58.6) (75.5) 
   Missing/invalid 11 1 1 (7.7) (84.6) (91.7) 6 3 4 (30.8) (46.2) (66.7) 9 0 4 (30.8) (69.2) (100.0) 
Race/ethnicity                   
   White 196 40 29 (10.9) (74.0) (83.1) 99 60 106 (40.0) (37.4) (62.3) 134 49 82 (30.9) (50.6) (73.2) 
   Black or African 
American 
1,060 230 218 (14.5) (70.3) (82.2) 570 343 595 (39.5) (37.8) (62.4) 824 235 449 (29.8) (54.6) (77.8) 
   Hispanic or Latino 248 51 32 (9.7) (74.9) (82.9) 180 80 71 (21.5) (54.4) (69.2) 211 69 51 (15.4) (63.7) (75.4) 
   Asian 9 1 0 (0.0) (90.0) (90.0) 3 4 3 (30.0) (30.0) (42.9) 7 3 0 (0.0) (70.0) (70.0) 
   American Indian or 
Alaska Native 
2 3 0 (0.0) (40.0) (40.0) 0 4 1 (20.0) (0.0) (0.0) 2 0 3 (60.0) (40.0) (100.0) 
   Native Hawaiian or 
Pacific Islander 
1 0 0 (0.0) (100.0) (100.0) 0 0 1 (100.0) (0.0) (0.0) 0 1 0 (0.0) (0.0) (0.0) 
   Multi-race 14 1 0 (0.0) (93.3) (93.3) 10 2 3 (20.0) (66.7) (83.3) 9 6 0 (0.0) (60.0) (60.0) 
   Declined 20 8 2 (6.7) (66.7) (71.4) 2 8 20 (66.7) (6.7) (20.0) 3 1 26 (86.7) (10.0) (75.0) 
   Don't know/not 
asked 
17 7 5 (17.2) (58.6) (70.8) 8 7 14 (48.3) (27.6) (53.3) 11 6 12 (41.4) (37.9) (64.7) 
   Missing/invalid 8 0 0 (0.0) (100.0) (100.0) 0 0 8 (100.0) (0.0) (0.0) 0 0 8 (100.0) (0.0) (0.0) 
Region                   
   Northeast 196 131 39 (10.7) (53.6) (59.9) 51 152 163 (44.5) (13.9) (25.1) 193 103 70 (19.1) (52.7) (65.2) 
   Midwest 103 18 24 (16.6) (71.0) (85.1) 49 23 73 (50.3) (33.8) (68.1) 82 28 35 (24.1) (56.6) (74.5) 
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Demographic 
characteristics 
Referred to partner services Interview for partner servicesa Referred to HIV prevention services 
Referred 
Not 
referred 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) 
Inter-
viewed 
Not 
inter-
viewed 
Missing 
/invalid 
(Missing 
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator 
%) Referred 
Not 
referred 
Missing 
/invalid 
(Missing
/invalid 
%) 
(Minimum 
indicator 
%) 
(Maximum 
indicator %) 
   South 1,087 173 202 (13.8) (74.4) (86.3) 638 286 538 (36.8) (43.6) (69.0) 772 187 503 (34.4) (52.8) (80.5) 
   West 86 15 20 (16.5) (71.1) (85.1) 36 41 44 (36.4) (29.8) (46.8) 71 28 22 (18.2) (58.7) (71.7) 
   U.S. dependent 
areas 
103 4 1 (0.9) (95.4) (96.3) 98 6 4 (3.7) (90.7) (94.2) 83 24 1 (0.9) (76.9) (77.6) 
Testing site type                   
   Health care 
facilities includes 
correctional facility 
clinics 
1,082 191 185 (12.7) (74.2) (85.0) 602 282 574 (39.4) (41.3) (68.1) 843 230 385 (26.4) (57.8) (78.6) 
   Non-health care 
facilities 
491 149 101 (13.6) (66.3) (76.7) 270 225 246 (33.2) (36.4) (54.5) 358 139 244 (32.9) (48.3) (72.0) 
   Missing/invalid 2 1 0 (0.0) (66.7) (66.7) 0 1 2 (66.7) (0.0) (0.0) 0 1 2 (66.7) (0.0) (0.0) 
Rapid test used in 
testing event 
                  
   Yes 1,010 267 211 (14.2) (67.9) (79.1) 556 395 537 (36.1) (37.4) (58.5) 835 290 363 (24.4) (56.1) (74.2) 
   No 565 74 75 (10.5) (79.1) (88.4) 316 113 285 (39.9) (44.3) (73.7) 366 80 268 (37.5) (51.3) (82.1) 
Total 1,575 341 286 (13.0) (71.5) (82.2) 872 508 822 (37.3) (39.6) (63.2) 1,201 370 631 (28.7) (54.5) (76.4) 
 
a Interview for partner services was not collected in the 2008-2011 version of the HIV testing form.  Therefore, these data are represented as missing/invalid data. 
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Table 16.  HIV testing and linkage to HIV medical care indicators in the United States, Puerto Rico, and the U.S. Virgin Islands, 2010-
2012. 
 
Demographic 
Characteristics 
2010 2011 2012 
HIV 
testing 
events 
Newly 
identified HIV-
positive 
testing events 
Linkage to HIV 
medical care within 
any timeframe 
HIV 
testing 
events 
Newly 
identified HIV-
positive 
testing events 
Linkage to HIV 
medical care within 
any timeframe 
HIV 
testing 
events 
Newly 
identified HIV-
positive 
testing events 
Linkage to HIV 
medical care within 
any timeframe 
No. No. (%) Linked Linkage % (Min-Max) No. No. (%) Linked 
Linkage % 
(Min-Max) No. No. (%) Linked 
Linkage % 
(Min-Max) 
Age at test (years)                               
<13 4,660 28 0.6 9 (32.1-90.0) 6,842 32 0.5 13 (40.6-72.2) 5,133 18 0.1 6 (33.3-54.5) 
13–19 258,683 581 0.2 181 (31.2-67.3) 336,134 617 0.2 206 (33.4-64.4) 303,523 606 3.6 288 (47.5-66.7) 
20–29 990,715 5,388 0.5 2,002 (37.2-70.7) 1,353,872 6,539 0.5 2,651 (40.5-70.2) 1,346,543 6,710 39.5 3,406 (50.8-67.5) 
30–39 512,563 3,466 0.7 1,303 (37.6-71.4) 701,634 4,062 0.6 1,698 (41.8-72.7) 725,598 4,083 24.1 2,186 (53.5-68.9) 
40–49 370,074 3,093 0.8 1,040 (33.6-69.1) 473,233 3,443 0.7 1,405 (40.8-70.5) 463,353 3,212 18.9 1,640 (51.1-66.8) 
50+ 299,982 2,163 0.7 770 (35.6-71.7) 400,901 2,328 0.6 904 (38.8-68.4) 423,382 2,296 13.5 1,152 (50.2-63.9) 
Gender 
               
Male 1,245,987 11,431 0.9 4,160 (36.4-70.5) 1,593,617 13,372 0.8 5,535 (41.4-70.6) 1,574,184 13,333 78.5 6,954 (52.2-67.5) 
Female 1,200,352 3,197 0.3 1,111 (34.8-71.3) 1,686,164 3,587 0.2 1,357 (37.8-71.1) 1,679,449 3,304 19.5 1,591 (48.2-65.9) 
Other specified … … … … … … … … … … 8,740 61 0.4 31 (50.8-58.5) 
Race/Ethnicity 
             
  
 
White 687,330 3,107 0.5 1,123 (36.1-69.3) 892,419 3,735 0.4 1,575 (42.2-72.0) 895,814 3,523 20.8 1,851 (52.5-67.1) 
Black or 
African/American 1,101,021 8,169 0.7 2,640 (32.3-67.6) 1,470,077 9,217 0.6 3,340 (36.2-66.9) 1,444,796 8,884 52.3 4,138 (46.6-63.8) 
Hispanic or Latino 520,787 2,793 0.5 1,304 (46.7-78.3) 683,241 3,427 0.5 1,761 (51.4-78.2) 686,757 3,497 20.6 2,219 (63.5-76.6) 
Asian 38,198 163 0.4 67 (41.1-67.7) 54,411 202 0.4 105 (52.0-82.7) 62,832 236 1.4 133 (56.4-68.9) 
American Indian or 
Alaska Native 12,188 59 0.5 13 (22.0-54.2) 16,500 55 0.3 16 (29.1-72.7) 16,566 87 0.5 33 (37.9-51.6) 
Native Hawaiian or 
Pacific Islander 5,750 40 0.7 19 (47.5-73.1) 8,443 42 0.5 21 (50.0-77.8) 8,148 41 0.2 24 (58.5-75.0) 
Multi-race 27,371 213 0.8 88 (41.3-84.6) 26,423 160 0.6 62 (38.8-70.5) 22,413 149 0.9 88 (59.1-69.8) 
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Demographic 
Characteristics 
2010 2011 2012 
HIV 
testing 
events 
Newly 
identified HIV-
positive 
testing events 
Linkage to HIV 
medical care within 
any timeframe 
HIV 
testing 
events 
Newly 
identified HIV-
positive 
testing events 
Linkage to HIV 
medical care within 
any timeframe 
HIV 
testing 
events 
Newly 
identified HIV-
positive 
testing events 
Linkage to HIV 
medical care within 
any timeframe 
No. No. (%) Linked Linkage % (Min-Max) No. No. (%) Linked 
Linkage % 
(Min-Max) No. No. (%) Linked 
Linkage % 
(Min-Max) 
 
Testing site type                  
Health care 
facilities including 
correctional facility 
clinics 
1,843,686 8,642 0.5 3,260 (37.7-71.6) 2,424,918 9,910 0.4 4,036 (40.7-68.1) 2,297,501 9,994 58.9 5,154 (51.6-67.9) 
Non-health care 
facilities 574,612 5,893 1.0 1,984 (33.7-69.2) 702,880 6,678 1.0 2,831 (42.4-75.0) 985,611 6,976 41.1 3,547 (50.8-66.1) 
Other facilities 33,545 189 0.6 40 (21.2-55.6) 130,117 529 0.4 95 (18.0-60.1) 2 0 0.0 … … 
Total 2,459,019 14,793 0.6 5,314 (35.9-70.6) 3,299,690 17,222 0.5 6,992 (40.6-70.7) 3,287,024 16,976 0.5 8,702 (51.3-67.1) 
Note:  Only jurisdictions with test-level data are included in this table.  52 jurisdictions were included in 2010, 55 in 2011, and 59 in 2012. 
